08/29/2010

Kidney Cancer 101: Learn Here

Sat, 28 Aug 2010 22:37:52 GMT

View Dr. David Minor's excellent slide set from the recent meeting of kidney cancer survivors held in San Francisco. You'll learn the basics about kidney cancer and about the drugs used to treat advanced disease.

Kidney 2010 Intro

08/28/2010

Join the International Kidney Cancer Alliance

Fri, 27 Aug 2010 19:53:15 GMT

Following a series of well-received meetings with patients, caregivers, and medical professionals in Spain, France, Germany, Italy, England, and Russia, among other countries, we're building the world's largest group of kidney cancer advocates— the International Kidney Cancer Alliance. Join us in Warsaw, Poland, in the spring of 2011. Details will be announced on our Facebook® Fan Page in the coming weeks. We know that some families are concerned about the issues that attend pharmaceutical company funding of patient activities. Although we have a long history of successful collaboration with industry, we remain sensitive to the needs of patients and their caregivers, so there will be no direct pharma involvement in the establishment of this ad-hoc group. Everyone is welcome to join and travel subsidies, based on demonstrated need, will be available.

We're working now to improve patient and physician education in Mexico, South America, Egypt, Eastern Europe, and China. Our publication, "We Have Kidney Cancer," will soon be available for immediate download in nine languages, too. Be sure to bookmark http://IKCA.org and check back for more information.

08/27/2010

Solid Variant of Papillary Renal Cell Carcinoma With Spindle Cell and Tubular Components

Tue, 24 Aug 2010 14:47:45 GMT

We report a case of solid variant of papillary renal cell carcinoma affecting a young man and provide histologic and clinical follow-up data, adding an additional case of this extremely rare pathology to the literature

08/24/2010

Differentiation of oncocytoma and renal cell carcinoma in small renal masses

Tue, 24 Aug 2010 14:49:10 GMT

We investigate the use of 4-phase computerized tomography with intravenous contrast to help distinguish oncocytoma from renal cell carcinoma (RCC) in tumors <4 cm.

08/24/2010

Virtual colonoscopy catches more, study finds

Sun, 22 Aug 2010 13:26:31 GMT

Now, a new study suggests that virtual colonoscopy may even be superior because it can identify cancers outside of the colon.

08/22/2010

Kidney patient gets transplanted to television

Sun, 22 Aug 2010 13:28:48 GMT

A kidney transplant patient, whose need for a new organ led to the discovery of his ex-partner having kidney cancer, has appeared on television.

08/22/2010

Lack of KISS1R expression is associated with rapid progression of conventional renal cell carcinomas

Sun, 22 Aug 2010 13:30:06 GMT

Expression of the KISS1R protein can be used for estimating the prognosis of conventional RCCs.

08/22/2010

Is advanced renal cell carcinoma becoming a chronic disease?

Fri, 20 Aug 2010 12:16:37 GMT

Cora Sternberg and colleagues 1 reported the efficacy of the multitargeted receptor tyrosine kinase inhibitor pazopanib for the treatment of metastatic renal cell carcinoma (RCC).

08/20/2010

Top Abstracts in Renal Cancer

Thu, 19 Aug 2010 14:32:26 GMT

TopAbstracts in Renal Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.

08/19/2010

Vanishing Cancers: Sometimes the disease simply disappears

Tue, 17 Aug 2010 13:24:11 GMT

Research has shown that spontaneous regression of cancer occurs in cases of advanced melanoma, advanced kidney cancer and neuroblastoma (a childhood cancer of nerve tissue). Regression also occurs in colonic adenomas (precancerous growths of the colon) and in precancerous lesions of the cervix.

08/17/2010

Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma

Sun, 15 Aug 2010 01:32:15 GMT

The results suggest that DKK1 may not be involved in the betacatenin dependent pathway.

08/14/2010

Billionaire Giving Pledge Is A Bad Idea

Wed, 11 Aug 2010 15:28:32 GMT

This interesting interview with Peter Kramer, a German billionaire who objects to the Buffet/Gates challenge, puts forward an alternative and somewhat unflattering view of that effort, claiming that it runs counter to the democratically legitimate state. NPQ has raised this issue in previous Newswiressome have voiced concern that the infusion of massive amounts of money into government systems may result in undue influence being exerted by those with enormous wealth.

08/11/2010

GenSpera Receives Additional Patent

Wed, 11 Aug 2010 18:00:06 GMT

G-202 was shown to ablate tumors in animal models of breast cancer, prostate cancer and kidney cancer.

08/11/2010

Latest Increase in U.S. Obesity Rate Will Mean More Cancers

Mon, 09 Aug 2010 15:54:02 GMT

The AICR experts pointed out that those 72.5 million Americans face an increased risk for colorectal cancer, postmenopausal breast cancer, kidney cancer, esophageal cancer, endometrial cancer, pancreatic cancer and gallbladder cancer.

08/09/2010

Surviving Kidney Cancer

Mon, 09 Aug 2010 16:33:04 GMT

Sgt. George Alderete and Judith Buelow are just two of the survivors now being seen in survivorship clinics at MD Anderson, as the institution embraces another component of the cancer care cycle survivorship.

08/09/2010

Virginia and Missouri fire shots over Obamacare's bow

Mon, 09 Aug 2010 15:56:56 GMT

Since Obama signed healthcare reform into law, 22 states have filed lawsuits challenging the constitutionality of reform; at least 36 states have introduced initiatives repealing all or parts of healthcare reform. Aside from the obvious political ramifications, what does this obvious sign of discontent mean for our healthcare system moving forward?

08/08/2010

Doctors say treatments using adult stem cells show promise

Mon, 02 Aug 2010 17:23:04 GMT

The idea is to transplant cells to produce a new immune system that will attack the diseases. Earlier work around a decade ago failed to give lasting benefit, but new approaches aim for better results, said Dr. Michael Bishop of the National Cancer Institute.

08/06/2010

Molecular Diagnostics Conference In Denver To Be Hosted By American Association For Cancer Research

Fri, 06 Aug 2010 18:12:22 GMT

Findings presented at this year's meeting will include new data on phase III kidney cancer drugs in development.

08/06/2010

Lpath, the Category Leader of Lipidomics-Based Therapeutics, Provides Status Update

Fri, 06 Aug 2010 18:14:38 GMT

ASONEP, as a single agent in naive mice, significantly delays progression of disease in Renal Cell Carcinoma ("RCC").

08/06/2010

Advances in Renal Cancer Journalists Award 2011 announced

Fri, 06 Aug 2010 18:16:18 GMT

Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European Advances in Renal Cancer Journalists Award 2011.

08/06/2010

Biomarkers Predicting Outcome in Patients With Advanced Renal Cell Carcinoma

Fri, 06 Aug 2010 18:20:58 GMT

Univariable analyses of baseline levels in the placebo cohort identified VEGF, CAIX, TIMP1, and Ras p21 as prognostic biomarkers for survival.

08/06/2010

Wife vows to starve herself if NHS won't help her husband

Sat, 31 Jul 2010 18:14:26 GMT

Terence Burch, 65, was hit by staphylococcus aureus, a neck infection, and kidney cancer.

07/31/2010

Kidney Cancer Blog Has Info That Could Save Your Life

Sat, 31 Jul 2010 18:20:20 GMT

The Kidney Cancer Association has launched a new blog, Survive Kidney Cancer, on Wordpress.com. Bill Bro, Kidney Cancer Association CEO, says, "We believe this to be the most comprehensive blog about kidney cancer to be found anywhere on the web." The blog, located at www.SurviveKidneyCancer.com, was adapted from the Association's publication for patients, "We Have Kidney Cancer," a 100+ page book that may be downloaded free of charge on the organization's website.

07/31/2010

Cedar Hill woman turns her misery into ministry

Sat, 31 Jul 2010 18:37:17 GMT

Jennifer Cox has weathered storms of uncertainty, disease and sadness.

07/31/2010

"Advances in Renal Cancer" Journalists' Award 2011 announced Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer

Fri, 06 Aug 2010 19:53:17 GMT

Leverkusen, July 2010 - Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European "Advances in Renal Cancer" Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film.

"Malignant tumors in kidney cells are one of the most insidious types of cancer worldwide. They are often only diagnosed at a late stage and have a significant unmet medical need", says Helmut Schäfers, Head of Corporate Communications Europe, Bayer HealthCare, Leverkusen, Germany. "By announcing this award together with specialists in this field, we want to stimulate journalists to report on the disease and publish more information about renal carcinoma and current medical developments." Carrie Konosky, Director of Development & Public Affairs, Kidney Cancer Association, USA, explains: "Our objective is to raise awareness of the symptoms and risk factors of renal cancer and inform the public about new, diagnostic therapy options. That is why the media are an important partner for us."

Journalists may submit their applications by March 1, 2011, to the Kidney Cancer Association - Project Office, P.O. Box 90 06 48, 51116 Cologne, Germany. The statutes are also available for download online at Bayer HealthCare’s press portal at http://www.viva.vita.bayerhealthcare.com.

The relevant stories must have been published between March 1, 2010, and February 28, 2011. The jury will award the prize to what seems to be the year’s most outstanding medical journalistic publication or program in Europe.

Members of the jury are up to four representatives from journalistic organizations, one urologist and one oncologist, one member of the Kidney Cancer Association as well as one non-voting representative from Bayer HealthCare. The award will be presented in Warsaw, Poland, in May 2011.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the health care and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover, manufacture and market products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.

About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at http://www.bayerscheringpharma.de.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contact:
Bayer HealthCare AG
Helmut Schäfers, Tel. +49 214 30-58308
E-Mail: mailto:helmut.schaefers@bayerhealthcare.com

The full story can be found in BayNews.
http://WWW.BayNews.BAYER.DE/BayNews/BayNews.nsf/id/2010-0365-e

07/20/2010

Penn State Lift For Life Raises More Than $98,000.00

Mon, 12 Jul 2010 19:47:04 GMT

The record total was nearly $16,000 more than was raised last year and a far cry from the $13,000 raised in the events first year in 2003. Thanks to generous sponsors, fans and the participating Nittany Lion football players, Lift For Life has now raised an eight-year total of nearly $500,000 for the Kidney Cancer Association.

07/17/2010

When Kidney Cancer Hits the Vena Cava

Wed, 14 Jul 2010 14:55:50 GMT

Its a nasty-looking chunk of cancer, a plug of renal cell carcinoma that sometimes finds its way into the inferior vena cava. Because of its location in the bodys largest vein and its potential threat to the heart and brain, this tumor thrombus is serious indeed.

07/14/2010

Kidney Removal Suggested Not To Prolong Life of Elderly

Wed, 14 Jul 2010 14:59:32 GMT

A new study has suggested that removing a kidney does not seem to prolong the life of patients aged 75 and above suffering with kidney cancer that has not spread.

07/14/2010

Lift for Life Raises New Record Total

Wed, 14 Jul 2010 15:00:58 GMT

Despite sweltering conditions in Holuba Hall, the eighth annual Penn State Uplifting Athletes Lift For Life was a huge success drawing more than 3,000 fans and raising a record total of $98,461.35 to benefit the Kidney Cancer Association.

07/14/2010

Nationally-Recognized Oncologist Joins Cedars-Sinais Samuel Oschin Comprehensive Cancer Institute

Tue, 13 Jul 2010 14:15:30 GMT

Figlin, a prolific researcher known for his work on new urologic and lung cancer treatments, will help manage the institutes growing clinical trials program, in which more than 100 studies are being conducted. As leader of the hematology/oncology division, he will oversee breast, prostate, lung, blood and bone cancer programs.

07/13/2010

Penn State football players raise $98,461.35 for kidney cancer research

Tue, 13 Jul 2010 17:16:18 GMT

It may have been hot on Holuba Hall on Friday but that did not keep players form Penn State's football team from raising a record amount of money to be put toward kidney cancer research. More than 3,000 fans came out in support of the Nittany Lions as the team raised $98,461.35 for the Kidney Cancer Association.

07/13/2010

Nanoparticles Shrink Tumors in Mice

Mon, 12 Jul 2010 14:09:20 GMT

The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.

07/12/2010

First Patient Treated in Galil Medical's TRACE Renal Registry

Sat, 10 Jul 2010 15:02:43 GMT

Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, today announced that Vanderbilt University Medical Center in Nashville, Tenn., has treated the first patient to be included in its new patient registry. The registry, called Tracking Renal Tumors After Cryoablation Evaluation (TRACE), will allow physicians and the company to follow and evaluate the use and effectiveness of cryotherapy treatment for patients with renal (kidney) tumors.

07/10/2010

PHOTO GALLERY: 2010 Penn State Lift for Life

Sat, 10 Jul 2010 15:13:10 GMT

Nate Stupar pours ice on his neck after completing the course during the Penn State Football Uplifting Athletes' Eighth Annual Lift for Life in Holuba Hall. Players form teams of four and compete in an 11 event challenge with exercises ranging from bench pressing to a giant tire flip. Proceeds from the event benefit the Kidney Cancer Association.

07/10/2010

Facebook Ad Campaign Raises Awareness

Sat, 10 Jul 2010 15:19:43 GMT

"We want to conquer kidney cancer in your lifetime," says KCA CEO Bill Bro, a 21-year survivor of kidney cancer. "Like many patients, my diagnosis came as the result of something unrelated. Because kidney cancer doesn't have obvious symptoms, it is often overlooked by both patients and doctors."

07/09/2010

Survivor Gets Back on Course

Sat, 10 Jul 2010 15:20:22 GMT

He told me I had a mass on my kidney, about 17 centimeters in size and it was called kidney cancer, recalled Kidwell.

07/09/2010

Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus

Fri, 09 Jul 2010 14:35:16 GMT

Conclusion: Radical nephrectomy and level IV tumour thrombectomy is associated with significant mortality.

07/09/2010

New findings from University Hospital, Department of Urology in the area of renal cell carcinoma described

Fri, 09 Jul 2010 14:36:49 GMT

Scientists discuss in 'Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less-which is aggressive cancer' new findings in renal cell carcinoma.

07/09/2010

Didcot cancer patient's death linked to drug trial

Fri, 09 Jul 2010 14:38:29 GMT

A kidney cancer patient died from a rare reaction to a life-extending drug he was taking as part of a trial, an inquest heard.

07/09/2010

Renal Cancer Associated With Recurrent Spontaneous Pneumothorax In Birt-Hogg-Dube Syndrome

Thu, 08 Jul 2010 21:51:12 GMT

The authors suggest that a diagnosis of Birt-Hogg-Dubé syndrome be considered in cases of recurrent pneumothorax, and affected individuals must be screened for renal tumours.

07/08/2010

Abscess Formation Mimicking Disease Progression

Thu, 08 Jul 2010 21:52:47 GMT

The authors discuss a case of intra-abdominal abscess formation mimicking disease progression during sunitinib treatment.

07/08/2010

Exceeding Contrast Dose Threshold Increases Risk of Acute Kidney Injury

Thu, 08 Jul 2010 21:57:58 GMT

We recommend that [maximum allowable contrast dose] should be determined before the procedure and implemented whenever feasible, they write.

07/08/2010

Cancer Treatment Based on Patient's Own Cells

Wed, 07 Jul 2010 22:16:01 GMT

Medistem Panama, licensee of Medistem Inc., announced today issuance of US patent # 7,749,495 covering a new method for treating cancer that does not require use of chemotherapy or radiation. The procedure, which involves taking out patient cells, manipulating them, and re-introducing them into the body, has demonstrated positive results in patients with metastatic renal cell carcinoma, neuroblastoma, adenocarcinoma, breast cancer, sarcoma, and rectal cancer.

07/07/2010

Ill ex-prison employees blame work program

Wed, 07 Jul 2010 22:17:17 GMT

They claim exposure to unsafe levels of heavy metals and toxic materials

07/07/2010

Rosetta Genomics and Collaborators Demonstrate MicroRNAs Accurately Sub-Classify Renal Tumors

Wed, 07 Jul 2010 22:18:40 GMT

Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a peer-reviewed article entitled "Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression" has been published in the online version of The Journal of Molecular Diagnostics.

07/07/2010

Epithelioid angiomyolipoma of kidney with atypical nuclear features and intranuclear inclusions on cytology

Wed, 07 Jul 2010 22:20:04 GMT

Described herein are the cytological findings of epithelioid angiomyolipoma (EAML) of the kidney with atypical nuclear features mistaken for renal cell carcinoma (RCC) in a 61-year-old male patient.

07/07/2010

Macrophages and Immunologic Inflammation of the Kidney

Wed, 07 Jul 2010 22:21:47 GMT

This article advances the case that targeting macrophage activation and phenotype is leading to new therapies in the treatment of many acute and chronic kidney diseases.

07/07/2010

Pazopanib given conditional UK licence for advanced renal cell carcinoma

Wed, 07 Jul 2010 22:23:35 GMT

Pazopanib has been granted a conditional licence in the UK for first-line treatment of patients with advanced renal cell carcinoma.

07/07/2010

New Tool for Presurgical Detection of Kidney Cancers Helps to Avoid Unnecessary Surgeries

Wed, 07 Jul 2010 22:25:30 GMT

If approved by the U.S. Food and Drug Administration (FDA), this will be one of the first diagnostic scans which can differentiate not only identify a tumors origin and location, but also provide data on the type (histology) of that tumor. Armed with this information, physicians and patients will be able to make more informed treatment choices.

07/07/2010

Concomitant Tumor and Autoantigen Vaccination Supports Renal Cell Carcinoma Rejection

Tue, 06 Jul 2010 16:14:04 GMT

Efficient tumor vaccination frequently requires adjuvant. Concomitant induction of an autoimmune response is discussed as a means to strengthen a weak tumor Agspecific response.

07/06/2010

Use of gene expression profiling to predict survival in cancer

Tue, 06 Jul 2010 16:17:15 GMT

Duplicated 1q might be a secondary mutations associated with disease progression. Trisomy of 1q has also been linked to metastatic potential of colon and renal cell carcinomas.

07/06/2010

RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma

Tue, 06 Jul 2010 16:19:02 GMT

Vascular endothelial growth factors (VEGFs) are crucial regulators of angiogenesis and vasculogenesis.

07/06/2010

Charity Navigator: Kidney Cancer Association

Sat, 03 Jul 2010 13:49:17 GMT

Founded in 1990, the Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. We fund, promote, and collaborate with the National Cancer Institute, American Society for Clinical Oncology, American Urological Association, and other institutions on research projects

07/04/2010

Concurrent Multilocular Cystic Renal Cell Carcinoma and Leiomyoma in the Same Kidney

Sat, 03 Jul 2010 14:00:48 GMT

This is the first report of this kind of presentation.

07/04/2010

Bone metastases from renal cell carcinoma: patient survival after surgical treatment

Sun, 04 Jul 2010 15:08:35 GMT

Surgery is the primary treatment of skeletal metastases from renal cell carcinoma, because radiation and chemotherapy frequently are not effecting the survival.

07/04/2010

Total Pancreatectomy for Metastatic Renal Cell Carcinoma with Marked Extension into the Main Pancreatic Duct

Sat, 03 Jul 2010 13:52:03 GMT

The authors discuss an extremely rare case of pancreatic metastasis from RCC, with marked extension into the main pancreatic duct.

07/03/2010

Metastatic Tumor in the Colon from Renal Cell Carcinoma

Sat, 03 Jul 2010 13:53:04 GMT

The authors describe a rare case of a metastatic tumour in the colon arising from renal cell carcinoma.

07/03/2010

Pure Sarcomatous Recurrence of Clear Cell Renal Carcinoma Following Radical Nephrectomy and Dendritic Cell Vaccination

Sat, 03 Jul 2010 13:55:18 GMT

The authors discuss the patient's history and pathology images, treatments, and the potential effects of dentritic cell-tumor cell hybrid vaccination on the natural history of renal cell carcinoma.

07/03/2010

TLN-4601

Sat, 03 Jul 2010 13:57:42 GMT

TLN-4601, a small molecule derived from a nonpathogenic microorganism and TLN-232, a peptide used for the treatment of multiple oncology indications such as metastatic melanoma, renal cell carcinoma, and pancreatic cancer.

07/03/2010

Kidney cancer patients denied drug that can extend their lives

Fri, 02 Jul 2010 13:43:17 GMT

The National Institute for health and Clinical Excellence has turned down the drug called everolimus, also known as Afinitor, saying it does not offer enough benefit to patients to justify the cost.

07/02/2010

Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma

Fri, 02 Jul 2010 13:44:22 GMT

Multilocular cystic renal cell carcinoma is an uncommon low grade renal cell carcinoma with unique morphologic features. Its cytogenetic characteristics have not been fully investigated. Its relationship to typical clear cell renal cell carcinoma is uncertain.

07/02/2010

1H NMR Metabonomic Analysis in Renal Cell Carcinoma: a Possible Diagnostic Tool

Fri, 02 Jul 2010 13:46:01 GMT

1H NMR based metabonomic approach was applied in order to monitor the alterations of plasma metabolic profile in Renal Cell Carcinoma (RCC) patients and controls

07/02/2010

Treatment of Transitional Cell Cancer of the Renal Pelvis and Ureter in India at an Incredible Success Rate

Fri, 02 Jul 2010 13:47:07 GMT

Indian surgeons provide treatment of Transitional cell cancer of the renal pelvis and ureter with the best standards of Indian private healthcare system that can be truly described as being state-of-the-art.

07/02/2010

Report on Clinical Integration of New Cancer Developments

Fri, 02 Jul 2010 13:49:40 GMT

MDOUTLOOK®, the oncology intelligence initiative powered by The Arcas Group, today announced results from its 3rd Annual Quick Poll research launched following this month's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Within one week, 281 cancer treaters from 22 countries responded, making it the first market feedback available post-ASCO.

07/02/2010

Gene Mutation Linked to Kidney Cancer

Fri, 02 Jul 2010 13:53:58 GMT

A new probe by the British scientists into the commonest form of kidney cancer have unveiled a batch of new gene mutations linked to it, suggesting even this apparently "straightforward" cancer type can be divided into subtypes requiring tailored treatment.

07/02/2010

Preclinical Data for MGCD265

Thu, 01 Jul 2010 13:25:53 GMT

The company is providing a preliminary update on Trial 103 (the first stage of the Phase II program) in which MGCD265 is administered in combination with either erlotinib (Tarceva®) or docetaxel (Taxotere®) in solid tumor patients.

07/01/2010

Avastin May Cause Kidney Damage

Thu, 01 Jul 2010 13:27:20 GMT

Kidney problems are the second serious condition linked to the cancer drug. Last year it was found that some patients on Avastin were at elevated risk of intestinal perforations.

07/01/2010

Longtime football coach Ken Hovet dies of cancer

Thu, 01 Jul 2010 13:28:21 GMT

Longtime Howard County football coach Ken Hovet died Monday night after fighting kidney cancer for several months. He was 49.

07/01/2010

AVEO Pharmaceuticals Human Response Platform and Proprietary Mouse Models Featured in Nature Reviews Cancer

Thu, 01 Jul 2010 13:30:24 GMT

Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types.

07/01/2010

Laparo-endoscopic single-site (LESS) radical nephrectomy with renal vein thrombectomy: initial report

Thu, 01 Jul 2010 13:32:49 GMT

By combining trocar sites and extraction incision, Laparo-endoscopic Single-site Surgery (LESS) may provide less morbidity than traditional laparoscopy. Concerns continue about LESS for locally advanced tumors. We present our experience with LESS-radical nephrectomy with renal vein thrombectomy (LESS-RN-RVT).

07/01/2010

MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens

Thu, 01 Jul 2010 13:34:31 GMT

Renal cell carcinoma (RCC) is one of the leading causes of cancer mortality. Characterization of microRNA (miRNA) expression of RCC will help disclose new pathogenic pathways in tumourigenesis and progression and may lead to the development of molecular biomarkers and target-specific therapies for diagnosis, prognostication and treatment.

07/01/2010

Minimizing Blood Flow Interruption During Surgery Lowers Kidney Disease Risk

Thu, 01 Jul 2010 13:40:43 GMT

Interrupting blood flow for more than 20 to 25 minutes during kidney cancer surgery leads to a greater risk for patients developing chronic kidney disease, according to a new study.

07/01/2010

Robust Annual Growth in the Renal Cell Carcinoma Drug Market

Wed, 30 Jun 2010 14:20:18 GMT

The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma reveal that significant uptake of the angiogenesis inhibitor Votrient/Patorma will be driven by its use in treating advanced renal cell carcinoma, particularly in the first-line setting. As a result, Votrient/Patorma will become the market leader and will garner sales of nearly $630 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

06/30/2010

Father's Day offers a chance to celebrate for a grieving John McDonald

Wed, 30 Jun 2010 14:22:36 GMT

McDonald did it for his father, Jack, who died on June 14 after an eight-month ordeal with liver and kidney cancer.

06/30/2010

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Wed, 30 Jun 2010 14:26:31 GMT

This is an open-label, multi-center study to evaluate the safety of RAD001 in Chinese patients with metastatic renal cell cancer who are intolerant of or have progressed despite treatment with vascular endothelial growth factor (VEGF)-targeted therapies.

06/30/2010

Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis

Wed, 30 Jun 2010 14:29:46 GMT

TNF antagonist induced psoriasis is a welldescribed adverse event without any known predisposing risk factors.

06/30/2010

The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma

Wed, 30 Jun 2010 14:30:46 GMT

Patients with a family history of ccRCC have pathological and clinical outcomes similar to patients with sporadic ccRCC.

06/30/2010

Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy

Wed, 30 Jun 2010 14:31:52 GMT

Carbonic anhydrase IX is a promising target for improving diagnosis, prognosis, and therapy of renal cell carcinoma (RCC) patients.

06/30/2010

Predicting Occult Multifocality of Renal Cell Carcinoma

Wed, 30 Jun 2010 14:33:00 GMT

The data suggest that occult multifocal RCC is more frequently associated with small (24 cm) renal lesions.

06/30/2010

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma

Wed, 30 Jun 2010 14:34:05 GMT

This review will summarize what is known about the fundamental biology that underlies clear cell RCC,

06/30/2010

NexMed to Present PrevOnco® Data at ILCA Annual Conference

Wed, 30 Jun 2010 14:35:38 GMT

The presentation, entitled, PrevOnco® Exhibits In Vitro Cytolytic Activity, Prolongs Survival in Kidney Cancer and Leukemia Models and Reduces Tumor Growth Rates Alone and in Concert in a Liver Cancer Model, is scheduled to be presented by Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, on Saturday, September 11, 2010 from 2:30 - 4:30 p.m.

06/30/2010

Perifosine phase II clinical studies

Wed, 30 Jun 2010 14:38:12 GMT

Perifosine is also in current multiple phase II clinical studies, including renal cell carcinoma.

06/30/2010

PrevOnco Prolongs Survival in Kidney Cancer

Tue, 29 Jun 2010 14:35:32 GMT

"PrevOnco(R) Exhibits In Vitro Cytolytic Activity, Prolongs Survival in Kidney Cancer and Leukemia Models and Reduces Tumor Growth Rates Alone and in Concert in a Liver Cancer Model"

06/29/2010

IMA901 has completed a successful Phase II trial in renal cell carcinoma

Tue, 29 Jun 2010 14:39:18 GMT

Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH ("immatics") to explore the development of novel ImmunoBody® vaccines.

06/29/2010

Rob Fowler's Mustache Art Show

Tue, 29 Jun 2010 14:42:41 GMT

Fowler survived kidney cancer a few years ago and shaved his infamous strip of hair to raise awareness . . .

06/29/2010

Phase I Study of Single-Agent AntiProgrammed Death-1 (MDX-1106) in Refractory Solid Tumors

Tue, 29 Jun 2010 14:46:49 GMT

Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of antiPD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.

06/29/2010

53-year-old fundraises for "life savers"

Tue, 29 Jun 2010 14:49:29 GMT

Glynis Zimmerman, of Hamilton Street, Parkeston, was diagnosed with double kidney cancer last September.

06/29/2010

Child cancer survivors have higher heart risk

Tue, 29 Jun 2010 14:51:53 GMT

Children and young people who survive cancer have a significantly higher risk of developing heart disease as young adults because of the cancer treatment they received, researchers said . . .

06/29/2010

Thalidomide has benefits

Mon, 28 Jun 2010 14:23:29 GMT

Thalidomide is now FDA-approved for the treatment of multiple myeloma. It has also been used to treat myelofibrosis, Kaposi sarcoma, and renal cell cancer along with the pain of leprosy. Many more uses for thalidomide are under study. Thalidomide is dangerous only when used in the wrong patients.

06/28/2010

Govt's. tardy response to BP oil catastrophe could destroy a major U.S. city

Mon, 28 Jun 2010 16:13:39 GMT

Benzene has been connected to a rare form of kidney cancer in two separate studies, one involving tank truck drivers, and the other involving seamen on tanker vessels, both carrying benzene-laden chemicals.

06/28/2010

Improvement of Psoriasis During Sunitinib Therapy for Renal Cell Carcinoma

Mon, 28 Jun 2010 14:30:28 GMT

The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions.

06/28/2010

Characteristics and clinical outcomes of renal cell carcinoma in children

Sun, 27 Jun 2010 14:24:50 GMT

The present study aimed to assess the clinicopathological characteristics and the prognosis of renal cell carcinoma (RCC) in children.

06/27/2010

Cancer Research UK launches hi-tech research centre

Sun, 27 Jun 2010 14:28:53 GMT

The Imperial Cancer Research UK Centre will see more than 200 clinicians and scientists from Imperial College Healthcare NHS Trust and Imperial College London working together to develop breakthrough treatments for the disease.

Philip O’Driscoll, 34, was treated using robotic surgery after he was diagnosed with kidney cancer in November 2009. He was treated at St Mary’s Hospital, part of Imperial College Healthcare.

Philip, a personal trainer, from Paddington, West London, said: “The tumour was only found by accident while I was being treated for an unrelated illness. I didn’t realise at the time that the robotic treatment I was having was so new.

06/27/2010

Fri, 25 Jun 2010 20:35:49 GMT

View the poster by clicking here

Abstract

Patient reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC)

Background: Multiple new therapies are now approved for patients (pts) with advanced RCC. As these agents enter widespread use, their perceived toxicities may differ from those reported in the literature and limit treatment duration and clinical outcomes. Patient reporting of toxicities may more accurately identify side effects most relevant to pts.

Methods: In an effort to collect patient-reported side effects from RCC pts treated with novel therapies, an on-line survey was developed. RCC pts were recruited through the Kidney Cancer Association.

Results: 177 pts completed the survey and 146 (64%M/36%F) received medication for RCC. Most common geographical regions were Midwest (20.8%); Northeast (17.4%); South/Southeast (16.7%); West (11.8%); and outside the U.S. (9.7%). 68 pts (47.2%) were treated at teaching hospitals; 55 pts (38.2%) in private oncology offices; and 21 pts (14.6%) at community hospitals. First-line treatments included sunitinib (Su) (52.1%, n=73); sorafenib (So) (15.7%, n=22); high dose IL-2 (14.3%, n=20); clinical trial (12.9%, n=18); bevacizumab (Bev) (5%, n=7); interferon (4.3%, n=6) and temsirolimus (Tem) (3.6%, n=5). The most common side effects reported for Su were fatigue (92.9%, n=65), altered taste (90%, n=63) and diarrhea (83.8%, n=57); So: hand foot syndrome (95.2%, n=20) and fatigue (95%, n=19); Bev: fatigue (83.3%, n=5) and altered taste (83.3%, n=5); Tem: fatigue, altered taste and rash (100%, n=4). Pts reported that the most difficult side effects from Su were diarrhea and fatigue (25%, n=18); So: hand foot syndrome (72.7%, n=16); Bev: fatigue (42.9%, n=3); Tem: rash (60%, n=3). Side effects necessitated changing the schedule, dose, or stopping Rx in 82% (n=18) of So pts and in 40% (n=28) of Su pts. QOL was affected very much/extremely for 56.6% of pts (n=73).

Conclusions: These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes.

06/25/2010

Couple sues Pratt & Whitney for wife's kidney cancer

Thu, 24 Jun 2010 16:53:28 GMT

An Acreage couple have filed a lawsuit against Pratt & Whitney, blaming the defense contractor for the wife's kidney cancer amid a state probe of an unsolved cancer cluster in their community.

06/24/2010

Common Cancer Drug Tied to Kidney Damage

Thu, 24 Jun 2010 14:04:31 GMT

Doctors should monitor patients taking bevacizumab (Avastin), researchers say.

06/24/2010

FDA Database Aims to Spark Orphan-Disease Drug Development

Thu, 24 Jun 2010 14:51:01 GMT

For months now, the Food and Drug Administration has been trying novel ways of encouraging drug makers to develop drugs for rare diseases.

06/24/2010

North Carolina Cancer Survivorship Summit

A new concept for non-invasive renal tumour ablation using real-time MRI-guided radiation therapy

Fri, 18 Jun 2010 15:49:35 GMT

Real-time MRI-guided radiation therapy using an MRI-accelerator might become a valuable non-invasive alternative to the current RCC treatment options.

06/18/2010

Eighth Annual Penn State Uplifting Athletes "Lift For Life" Set for July 9 to Benefit the Kidney Cancer Association

Fri, 18 Jun 2010 15:53:09 GMT

Penn State Football Uplifting Athletes announced today that the 2010 Lift for Life is set for Friday, July 9. with doors to Holuba Hall opening at 1:30 p.m. Proceeds again will benefit the Kidney Cancer Association.

06/18/2010

Robotic And Laparoscopic Partial Nephrectomy Without Vascular Clamping And Renal Ischemia

06/03/2010

"Advances in Renal Cancer" Journalists' Award 2011 announced

Wed, 02 Jun 2010 14:07:29 GMT

Leverkusen, May 2010 – Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European “Advances in Renal Cancer” Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film.

"Malignant tumors in kidney cells are one of the most insidious types of cancer worldwide. They are often only diagnosed at a late stage and have a significant unmet medical need”, says Helmut Schäfers, Head of Corporate Communications Europe, Bayer HealthCare, Leverkusen, Germany. “By announcing this award together with specialists in this field, we want to stimulate journalists to report on the disease and publish more information about renal carcinoma and current medical developments.” Carrie Konosky, Director of Development & Public Affairs, Kidney Cancer Association, USA, explains: “Our objective is to raise awareness of the symptoms and risk factors of renal cancer and inform the public about new, diagnostic therapy options. That is why the media are an important partner for us.”

Journalists may submit their applications by March 1, 2011, to the Kidney Cancer Association – Project Office, P.O. Box 90 06 48, 51116 Cologne, Germany. The statutes are also available for download online at Bayer HealthCare’s press portal at www.viva.vita.bayerhealthcare.com.

The relevant stories must have been published between March 1, 2010, and February 28, 2011. The jury will award the prize to what seems to be the year’s most outstanding medical journalistic publication or program in Europe.

Members of the jury are up to four representatives from journalistic organizations, one urologist and one oncologist, one member of the Kidney Cancer Association as well as one non-voting representative from Bayer HealthCare. The award will be presented in Warsaw, Poland, in May 2011.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the health care and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover, manufacture and market products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at www.bayerscheringpharma.de.

Contact:
Helmut Schäfers, Phone: +49 214 30-5830
E-mail: helmut.schaefers@bayerhealthcare.com

hs (2010-00xxE)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

06/01/2010

Metastatic Tumor in the Colon from Renal Cell Carcinoma

Tue, 01 Jun 2010 21:19:27 GMT

A 74-year-old male is admitted to hospital for dyspnoea. Findings from chest x-ray, computed tomography, and colonoscopy are described; images provided.

06/01/2010

Sunscreen Products Linked to Kidney Cancer

Mon, 31 May 2010 18:45:22 GMT

. . . chemicals poured into sunscreen products are equally dubious. They include:TEA, DEA, MEA (tri-, di- and mono- ethaloamines). These chemicals can cause liver and kidney cancer.

05/31/2010

Seattle Genetics Leads the Way in Next Generation Antibody Technologies

Mon, 31 May 2010 18:50:23 GMT

Seattle Genetics has two proprietary ADCs in the clinic, one in late stage trials for Hodgkins Lymphoma and a second in early stage trials for non-Hodgkins Lymphoma and Renal Cell Carcinoma.

05/31/2010

Pioneering cancer drug treatment goes on trial

Mon, 31 May 2010 19:05:03 GMT

A CANCER patient from Yorkshire has become the first in the world to trial a new drug experts hope will become part of a new generation of treatments against the disease.

05/31/2010

Readers share famous encounters

Sun, 30 May 2010 19:19:50 GMT

Not only did Bob meet Elvis Presley, he also ended up with a bottle of the King's Vaseline Hair Tonic. Inspired by this anecdote, I asked readers to send me their accounts of encounters with the famous.

05/30/2010

Cancer patient 'abandoned' by drug refusal

Sun, 30 May 2010 19:22:17 GMT

A CANCER patient last night said he felt "completely abandoned" after health chiefs refused to pay for a new drug which could prolong his life.

05/30/2010

Targeted agents for renal cell carcinoma

Sun, 30 May 2010 19:29:30 GMT

Proposals to use these agents as neoadjuvant therapy have generated significant controversy, Dr. Van Poppel said.

05/30/2010

Antibody diagnostic appears specific for clear cell renal cell carcinoma

Sun, 30 May 2010 19:32:02 GMT

Agent shows high preoperative sensitivity, specificity, data indicate.

05/30/2010

Cancer Vaccine Research Is Coming To Fruition

Fri, 28 May 2010 14:14:32 GMT

The launch of Sanofi Pasteur MSD's Gardasil and GSK's Cervarix has propelled cancer vaccines from research obscurity to a key area of commercial and clinical interest. But can the sector capitalise on these gains and really fulfil its promise?

05/28/2010

Imaging of advanced renal cell carcinoma

Thu, 27 May 2010 15:39:09 GMT

MDCT represents the diagnostic mainstay for the detection and staging of RCC. In the wake of new systemic therapies for advanced RCC, including angiogenesis inhibitor drugs, monitoring treatment response may become a new task for crosssectional imaging.

05/27/2010

Evaluation of neuroendocrine markers in renal cell carcinoma

Thu, 27 May 2010 15:39:55 GMT

Tumours with an immunopositivity for serotonin had a longer RCCspecific survival and tumours with an immunopositivity for CD56 and NSE had a shorter RCCspecific survival but the difference was not significant.

05/27/2010

Pfizer Oncology to Present New Clinical Data From Ten Molecules Across Multiple Tumor Type

Thu, 27 May 2010 15:44:20 GMT

Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets.

05/27/2010

Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis - Abstract

Tue, 25 May 2010 20:27:57 GMT

Department of Urology, University of Munich, Klinikum Grosshadern, Marchioninistr. 15, 81377, Munchen, Germany.

05/25/2010

Differential diagnosis of renal tumours with clear cell histology - Abstract

Tue, 25 May 2010 20:29:50 GMT

Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

05/25/2010

Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up

Tue, 25 May 2010 20:30:49 GMT

Clinical studies have confirmed that renal oncocytoma (RO) is a benign neoplasm with excellent prognosis. In diagnostically challenging cases of renal oncocytic epithelial neoplasms, fluorescent in-situ hybridization (FISH) is increasingly being used and its ability to distinguish RO from chromophobe renal cell carcinoma (ChRCC) has been documented.

05/25/2010

Using personalized vaccines, researchers enlist the immune system to oust tumors

Tue, 25 May 2010 20:32:06 GMT

The diagnosis of kidney cancerrenal cell carcinomawas shocking, Creel says.

05/25/2010

Leptomeningeal Carcinomatosis From Renal Cell Cancer: Treatment Attempt With Radiation And Sunitinib

Mon, 24 May 2010 14:01:37 GMT

The authors describe the case of leptomeningeal carcinomatosis in a 72-year-old male with known brain and lung metastases from renal cell cancer without previous systemic therapy.

05/24/2010

Lappin helped 'Make-A-Wish' dreams come true

Mon, 24 May 2010 14:03:48 GMT

After Todd Lappin was diagnosed with cancer he would tell people that the kidney doctors removed was never his favorite kidney.

05/24/2010

AVEO Pharma (AVEO) To Present Data from Tivozanib and AV-299 at ASCO 2010 Annual Meeting

Sat, 22 May 2010 15:11:49 GMT

We are pleased to have the opportunity to present additional analyses from our Phase 2 clinical trial of tivozanib in patients with renal cell cancer, as well as data from a Phase 1 clinical trial of AV-299 in collaboration with Merck . . .

05/22/2010

Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy

Sat, 22 May 2010 15:13:24 GMT

The objective of our study was to evaluate response assessment and predict clinical outcome in patients with metastatic renal cell carcinoma (RCC) receiving antiangiogenic targeted therapy. Target lesions were assessed on routine contrast-enhanced CT (CECT) images obtained during the portal venous phase using new response criteria.

05/22/2010

Imaging-Guided Percutaneous Renal Biopsy: Rationale and Approach

Sat, 22 May 2010 15:14:34 GMT

The purpose of this article is to discuss the history of, indications and rationale for, and approach to imaging-guided percutaneous renal biopsies.

05/22/2010

Predictive Factors for Ipsilateral Recurrence After Nephron-sparing Surgery in Renal Cell Carcinoma

Sat, 22 May 2010 15:15:47 GMT

RCC ipsilateral recurrence risk after NSS is significantly associated with tumour size . . .

05/22/2010

Eighth Annual Penn State Uplifting Athletes "Lift For Life" Set for July 9 to Benefit the Kidney Cancer Association

Sat, 22 May 2010 15:18:49 GMT

Nittany Lion Football Student-Athletes Have Raised Nearly $400,000 in Initial Seven Years

05/22/2010

Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC)

Fri, 21 May 2010 20:11:29 GMT

Tumor gene expression may impact prognosis following surgery for early stage ccRCC. Genomic analysis may also aid in understanding disease biology.

05/21/2010

About Interleukin 21

Fri, 21 May 2010 20:22:29 GMT

This novel immunotherapy has demonstrated antitumor activity in multiple tumor types (metastatic melanoma, renal cell cancer and non-Hodgkin's lymphoma) as a single agent and in combination with other therapies.

05/21/2010

Sorafenib safety profile

Fri, 21 May 2010 20:24:47 GMT

Long-term sorafenib safety profile in > 700 patients with renal cell carcinoma treated for 12 to 42 months.

05/21/2010

Redectane(R) Meets Both Endpoints Specificity And Sensitivity With Superiority Over CT In Its Pivotal Phase III Trial

Thu, 20 May 2010 13:52:15 GMT

The aim of the Phase III-REDECT study was to determine whether the combination of REDECTANE® with positron emission tomography (PET) and computer tomography (CT) versus the standard use of CT alone could improve the diagnosis of renal masses. Sensitivity and specificity were the defined endpoints of the study.

05/20/2010

Leptomeningeal Carcinomatosis From Renal Cell Cancer: Treatment Attempt With Radiation And Sunitinib

Thu, 20 May 2010 15:35:56 GMT

This case illustrates important issues around both biological behaviour and treatment approaches in metastatic renal cell cancer.

05/20/2010

Papillary Renal Cell Carcinoma With Cutaneous Metastases

Thu, 20 May 2010 15:37:08 GMT

The authors are reporting a unique case of papillary RCC with cutaneous metastases diagnosed at their institution.

05/20/2010

Use of Tumor Necrosis FactorAlpha-coated Gold Nanoparticles to Enhance Radiofrequency Ablation in a Translational Model of Renal Tumors

Thu, 20 May 2010 15:38:40 GMT

The authors have demonstrated the efficacy of CYT6091 in enhancing RFA in a translational kidney tumor model.

05/20/2010

The prognostic factors for patients with pT1a renal cell carcinoma

Thu, 20 May 2010 15:41:16 GMT

Although the prognosis of patients with pT1a stage renal cell carcinoma (RCC) is generally good, some of these patients show distant metastasis. In this study, we intended to identify the perioperative and pathologic prognostic factors for patients with pT1a stage RCC.

05/20/2010

Genetic Secrets of Common Kidney Cancer

Wed, 19 May 2010 15:10:46 GMT

By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.

05/19/2010

Renal Cancer Project ANYARA Featured in Journal of Immunotherapy

Wed, 19 May 2010 15:13:21 GMT

The results show that critical properties of ANYARA (naptumomab estafenatox), such as tumor reactivity and therapeutic window were improved.

05/19/2010

Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Wed, 19 May 2010 15:15:08 GMT

The authors conducted a retrospective study to investigate the overall survival (OS) of patients who underwent CN using the OS of patients with mRCC who did not undergo CN as a referent group.

05/19/2010

Immutep announces oral presentation at ASCO Annual Meeting of IMP321 final results in Phase I/II chemoimmunotherapy trial

Wed, 19 May 2010 15:18:11 GMT

A Phase I trial in metastatic renal cell carcinoma with IMP321 alone has been completed.

05/19/2010

Wilex German Biotech Meets FDA Phase 3 Endpoints for Renal Cancer Diagnosis

Wed, 19 May 2010 15:20:24 GMT

Based on these results, WILEX plans to submit REDECTANE® for approval by the US Food and Drug Administration (FDA) at the end of 2010.

05/19/2010

Management of side effects associated with antiangiogenic treatment in renal cell carcinoma

Wed, 19 May 2010 15:22:13 GMT

Clinicians have changed their practice and are faced with a number of new adverse events.

05/19/2010

Cancer drug policy has shocking flaws

Wed, 19 May 2010 15:26:07 GMT

Is an overstretched and underfunded National Health Service to blame?

05/19/2010

Kidney removal studied in kidney cancer

Tue, 18 May 2010 12:48:06 GMT

A Cleveland Clinic study suggests the removal of cancerous kidneys does not prolong the lives of patients 75 years or older.

05/18/2010

American Cancer Society awards 152 new research and training grants

Tue, 18 May 2010 12:51:57 GMT

Dr. Wendy Rathmell at the University of North Carolina has detected a novel protein, Ror2 which is abundant in renal cell tumors, particularly those with a very poor prognosis. Dr. Robert Huigens working at the University of Illinois is attempting to make the natural product, Englerin A, which was isolated in tiny quantities from a plant in Africa. Englerin A has generated excitement for showing highly potent and selective activity for elimination of renal cancer cells.

05/18/2010

Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients

Tue, 18 May 2010 12:55:04 GMT

Metachronous occurrence of RCC in the contralateral kidney is associated with an unfavorable prognosis . . .

05/18/2010

Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis

Tue, 18 May 2010 12:56:19 GMT

Liver metastasectomy is an independent valuable tool in the treatment of metastatic RCC . . .

05/18/2010

No, You Can't Keep Your Health Plan

Wed, 19 May 2010 00:13:38 GMT

Consolidated practices and salaried doctors will leave fewer options for patients and longer waiting times for routine appointments.

05/18/2010

IMBiotechnologies Receives FDA Clearance to Market Occlusin® 500 Biodegradable Microspheres in the U.S.

Mon, 17 May 2010 11:55:04 GMT

OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.

05/17/2010

Coverage of the 2010 Genitourinary Cancers Symposium

Mon, 17 May 2010 11:57:42 GMT

A CME activity from Clinical Care Options

05/17/2010

The role of radiologic imaging and biopsy in renal tumor ablation

Mon, 17 May 2010 12:27:33 GMT

The rate of unintentionally discovered renal masses has been increasing along with a parallel increased incidence of renal cell carcinoma both in men and women.

05/17/2010

Man dies after diseased-kidney transplant from wife

Mon, 17 May 2010 12:31:29 GMT

According to the Uwajima Tokushukai Hospital, the couple had asked the hospital in February whether it was possible to transplant the kidney from the wife, who had kidney cancer, to the husband.

05/17/2010

Presentations from Fifth European Kidney Cancer Symposium

Mon, 17 May 2010 19:24:02 GMT

Slides from the Fifth European International Kidney Cancer Symposium, held May 7 & 8, in London, England, are available online. Also online are selected presentations from the First European Kidney Cancer Nursing Conference.

05/17/2010

Fuhrman Grade Provides Higher Prognostic Accuracy Than Nucleolar Grade for Papillary Renal Cell Carcinoma

Sat, 15 May 2010 15:24:24 GMT

Each grading system performs well but the predictive accuracy of Fuhrman grade is statistically superior to that of nucleolar grade and only.

05/15/2010

Edgecomb yard sale for cancer organization

Sat, 15 May 2010 15:26:38 GMT

Plans are continuing for the June 4 and 5 yard sale at Edgecomb Town Hall, to benefit the Kidney Cancer Association.

05/15/2010

Generic Sutent On Horizon?

Fri, 14 May 2010 15:57:44 GMT

Mylan Inc. (MYL) has applied for U.S. regulatory approval to sell a generic version of Pfizer Inc.'s (PFE) Sutent cancer pill by challenging several patents on the drug.

05/14/2010

Tue, 04 May 2010 13:18:28 GMT

Multiple epidemiologic studies have linked the development of renal cancer to obesity. In this chapter, we begin with a review of selected population studies, followed by recent mechanistic discoveries that further link lipid deregulation to the RCC development.

05/04/2010

Thu, 29 Apr 2010 15:42:51 GMT

Click to read the article

04/29/2010

New Oral VEGF-TKI, Tivozanib, Demonstrates Robust Anti-tumor Activity and Excellent Safety in Advanced Kidney Cancer Patients Global Phase 3 TIVO-1 Trial Actively Recruiting

Thu, 29 Apr 2010 17:47:31 GMT

AVEO Pharmaceuticals has recently initiated enrollment in a Phase 3 clinical trial evaluating tivozanib – a new oral, once-daily, triple VEGF receptor inhibitor – in patients with advanced kidney cancer, with nearly 500 patients worldwide expected to participate. TIVO-1 is a randomized, controlled trial evaluating tivozanib compared to sorafenib (Nexavar®), an FDA and EMEA approved therapy for the treatment of advanced renal cell carcinoma (RCC). The primary endpoint of the trial is progression-free survival (PFS), while secondary endpoints include overall survival, objective response rate, duration of response and quality of life. As the lead study investigator, I am excited to be a part of this important study and pleased to report that trial enrollment at sites spanning the United States, Canada, Europe and Asia is well underway.

Results from a previously completed Phase 2 clinical study of tivozanib demonstrate characteristics of a highly differentiated therapy; patients with clear cell RCC who had undergone a prior nephrectomy achieved a median PFS of 14.8 months, with minimal side-effects commonly associated with other VEGF therapies (such as diarrhea, fatigue, rash, mucositis, stomatitis and hand-foot syndrome).

Individuals with RCC of clear cell histology that have had a prior nephrectomy and that have not received prior VEGF-targeted therapy are eligible for TIVO-1. If you think that you or one of your loved ones may be eligible, please contact AVEO Pharmaceuticals’ clinical operations department at clinicaltrials@aveopharma.com for additional information about eligibility criteria and to locate a trial site near you.

04/29/2010

Cancer research suggests changes in treatment may be forthcoming

Wed, 28 Apr 2010 14:37:48 GMT

Patients were placed into five marker groups. A first subset was assigned to one of four drugs without regard to their biomarkers. Patients in a second wave were assigned to drugs based on their particular tumor biomarkers, taking into consideration how people in the first group with similar biomarkers were faring.

04/28/2010

Widower calls for end to drug 'lottery'

Wed, 28 Apr 2010 14:15:49 GMT

She was told there was only one treatment a £30,000 a year drug called sutent but she couldnt have it.

04/28/2010

Renal Cell Neoplasms of Oncocytosis Have Distinct Morphologic, Immunohistochemical, and Cytogenetic Profiles

Wed, 28 Apr 2010 14:18:12 GMT

This study was undertaken to elucidate the genetic patterns of the renal cell neoplasms of oncocytosis and to compare them with those found in cases with multiple oncocytomas.

04/28/2010

NEW! 20th Anniversary 'Survivor' Wristbands

Wed, 28 Apr 2010 19:22:50 GMT

Five (5) Kidney Cancer Association Limited Edition 20th Anniversary Survivor Orange | Yellow | Green Wristbands for only $6.99. Medium-size silicone wristbands are imprinted with "Kidney Cancer Survivor" our website address. Give these as gifts to help spread awareness of kidney cancer and the need for a cure. People will ask you, "What does the orange, yellow, and green band stand for?" Orange = surviving kidney cancer | Yellow = honoring Lance Armstrong for putting the focus on surviving cancer | Green = kidney cancer (the disease itself).

Click here to order now!

04/28/2010

T-Cell Receptor Gene-Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy

Wed, 28 Apr 2010 14:39:04 GMT

Adoptive therapy with genetically engineered T cells carrying redirected antigen specificity is a new option for the treatment of cancer. This approach is not yet available for metastatic renal cell carcinoma (RCC), due to the scarcity of therapeutically useful reagents. We analyzed tumor-infiltrating lymphocytes (TIL) from RCC to identify T-cell specificities with shared tumor-specific recognition to develop T-cell receptor (TCR)-engineered T lymphocytes for adoptive therapy of RCC.

04/27/2010

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

Tue, 27 Apr 2010 15:47:39 GMT

To evaluate the efficacy and toxicity of the combination of bevacizumab, an angiogenesis inhibitor, and everolimus, an mTOR inhibitor, in the treatment of patients with advanced clear cell renal carcinoma.

04/27/2010

ASVT Champions Dethroned

Tue, 27 Apr 2010 15:49:32 GMT

Alpha Tau Omega, with the help of Twiin Productions, hosted the event at the East Beach Volleyball Courts in downtown Santa Barbara. Approximately 4,000 people attended the tournament, which featured music, food, a beer garden and plenty of volleyball. All proceeds from ticket sales were donated to the Kidney Cancer Association.

04/27/2010

What's CAREFLASH.COM?

Mon, 26 Apr 2010 01:55:43 GMT

Jay Drayer, CEO of CAREFLASH.COM explains what makes this social network so unique. Learn why this virtual community is better than others for families dealing with a loved one's kidney cancer. Click the media player link (above) to hear the interview. Then, be sure to visit CAREFLASH.COM.

04/26/2010

Smile For Your Child: A Parent's Guide To Finding Positive Energy During Diagnosis, Treatment, & Life After

Tue, 27 Apr 2010 01:24:49 GMT

Author Tracy R. Gray discusses her book, Smile For Your Child: A Parent's Guide To Finding Positive Energy During Diagnosis, Treatment, & Life After, in this thirty-minute interview with Bill Bro, of the Kidney Cancer Association. Gray's son is a survivor of Wilms Tumor, a pediatric malignancy.

04/26/2010

Carew's work ethic outlasted retirement

Sun, 25 Apr 2010 15:27:09 GMT

Charles Chuck V. Carew worked well beyond retirement, not stopping until cancer made it physically impossible. In fact, the U.S. Postal Service worker and Air Force retiree stayed on the job until three months before his 76th birthday.

04/25/2010

Some of world's leading experts address UK patients

Sun, 25 Apr 2010 15:35:14 GMT

World experts in the treatment of kidney cancer will gather in London 06 May 2010 to discuss cutting-edge treatments with patients and their family members. Also on the expert panel, a barrister who handles patient appeals to NICE. Travel subsidies for the indigent living in Europe are available. See "Calendar of Events" at http://kidneycancer.org for details.

04/25/2010

Welsh nurses receive lesson in cancer care

Sun, 25 Apr 2010 16:28:46 GMT

This informative all-day meeting gave over 40 nurses from across Wales the opportunity to learn more about kidney cancer and improve patient care and their understanding of the disease.

04/25/2010

First European Kidney Cancer Nursing Conference Agenda

Sun, 25 Apr 2010 16:36:33 GMT

07 May 2010, London. View the agenda or register here: http://www.kidneycancer.org/knowledge/learn/medical-education-programs.

04/25/2010

Dunk tank fundraiser to benefit Kidney Cancer Association

Sat, 24 Apr 2010 19:24:54 GMT

Penn State Football Uplifting Athletes has announced that nine current players will be participating in a dunk tank fundraiser from 5-7 p.m. on Friday (April 23) near Beaver Stadium as part of Blue-White Weekend presented by AAA.

04/24/2010

A prospective study of one-carbon metabolism biomarkers and risk of renal cell carcinoma

Sat, 24 Apr 2010 19:29:53 GMT

Previous studies have found associations between one-carbon metabolism factors and risk of several cancers, but little is known regarding renal cell carcinoma (RCC). We conducted a nested casecontrol study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, a prospective study of Finnish male smokers aged 5069 at baseline.

04/24/2010

Renal Cell (Kidney) Cancer Forum & Blog

Sat, 24 Apr 2010 19:33:27 GMT

Ask Dr. Anthony Ciarallo a Question Regarding Adult Renal Cell (Kidney) Cancer [forum section]

04/24/2010

Tumors Deficient in a Specific Enzyme Are Sensitive to a New Drug 'ADI-PEG 20'

Thu, 22 Apr 2010 12:55:49 GMT

He et al also established primary renal cell carcinoma cultures from fresh human tumor biopsies which were ASS-deficient. ADI-PEG 20 inhibited growth of these cells. These findings suggest that ASS deficiency may serve as a biomarker for selecting tumors for targeted therapy with ADI-PEG 20.

04/22/2010

Seattle Genetics Highlights ADC and SEA Technologies at AACR

Thu, 22 Apr 2010 12:58:02 GMT

These findings illustrate the mechanism for the release of cysteine-mcMMAF after internalization of the ADC into target cells (Abstract #5334). SGN-75 is in an ongoing phase I clinical trial for CD70-positive relapsed/refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma.

04/22/2010

Renal Cell Carcinoma Mortality Calculator

Thu, 22 Apr 2010 16:46:25 GMT

Is it a tool or a toy? You can decide. Bear in mind, no two cases are exactly alike.

04/22/2010

MethylGene Presents Preclinical Data for MGCD265 (A Multi-Targeted Met Kinase Inhibitor) at the American Association for Cancer Research (AACR) Annual Meeting

Wed, 21 Apr 2010 12:01:28 GMT

MGCD265 is an oral multi-targeted receptor tyrosine kinase inhibitor currently in multiple clinical trials. MGCD265 targets Met and blocks Met activities which contribute to cancer development and progression such as cell proliferation, motility, angiogenesis and tumor cell survival.

04/21/2010

Conservative surgery not inferior to nephrectomy

Tue, 20 Apr 2010 12:25:45 GMT

EORTC releases results of 30904 study on kidney cancer.

04/20/2010

Surgery still the only measure to cure RCC

Tue, 20 Apr 2010 12:27:51 GMT

"Surgery in an early stage always was and still is the only measure to cure RCC, and surgery plays an important role in the treatment of metastases as long as they can be removed completely," said Prof. Günter Janetschek.

04/20/2010

Real estate exec Hal Wilson dies at age of 66

Sun, 18 Apr 2010 13:08:51 GMT

Hal Wilson, the real estate executive who established The Wilson Group real estate sales firm, died early Friday at the age of 66 as a result of cancer.

04/18/2010

EAU: Advances in kidney cancer management

Sun, 18 Apr 2010 13:10:24 GMT

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

04/18/2010

Husband's fury at NHS selling dying wife's cancer drug abroad

Fri, 16 Apr 2010 12:16:24 GMT

Bill Phelps spoke out after a Surrey hospital trust was criticised for selling more than £4million of drugs abroad to make profits of more than £300,000.

04/16/2010

Identifying the risk of disease progression after surgery for localized renal cell carcinoma

Fri, 16 Apr 2010 12:18:10 GMT

To identify factors in a large cohort of patients with pathologically localized renal cell carcinoma (RCC) that predicted disease progression after surgery, as RCC most commonly presents as a localized tumour which is treated with surgical excision.

04/16/2010

Durable oncologic outcomes after radiofrequency ablation

Fri, 16 Apr 2010 12:19:29 GMT

Experience from treating 243 small renal masses over 7.5 years.

04/16/2010

Podocalyxin EBP50 Ezrin Molecular Complex Enhances the Metastatic Potential of Renal Cell Carcinoma

Fri, 16 Apr 2010 12:21:33 GMT

Podocalyxin was initially identified in glomerular podocytes to critically maintain the structural and functional integrity of the glomerular ultrafiltrative apparatus.

04/16/2010

Renal Cell Carcinoma Drug Discoveries - What the Future Holds

Thu, 15 Apr 2010 13:26:10 GMT

This is a very exciting time in the treatment of renal cell carcinoma (RCC) . . .

04/15/2010

Funding for kidney cancer drug withheld

Thu, 15 Apr 2010 13:29:40 GMT

Kidney cancer sufferers received a blow after funding for a new drug was refused.

04/15/2010

Investigators target vascular endothelial growth factor

Thu, 15 Apr 2010 13:30:37 GMT

A new study, 'The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma,' is now available. In this recently published article, scientists in Amsterdam, Netherlands conducted a study "To investigate the relationship between angiogenesis and coagulation markers in tumor tissues of primary renal cell carcinoma (RCC). Tumors stimulate angiogenesis and activate the coagulation cascade."

04/15/2010

Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma

Thu, 15 Apr 2010 13:31:53 GMT

Multilocular cystic renal cell carcinoma is an uncommon low grade renal cell carcinoma with unique morphologic features. Its cytogenetic characteristics have not been fully investigated.

04/15/2010

Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma

Thu, 15 Apr 2010 13:33:11 GMT

After 6 wk of treatment, a significant downstaging of the disease and complete disappearance of the metastases were noticed on computed tomography scan.

04/15/2010

Pfizer Oncology to present cancer drugs at annual cancer research conference

Thu, 15 Apr 2010 13:35:14 GMT

The company will present data on investigational cancer drugs such as figitumumab, a monoclonal antibody for lung cancer, as well as Sutent (sunitinib) and the kidney cancer drug axitinib, as well as drugs for lymphoma and others.

04/15/2010

Green Tea "Promising Agent" in Kidney Cancer

Thu, 15 Apr 2010 13:49:35 GMT

Green tea may be an effective anticancer agent for renal cell carcinoma(or RCC), the most common type of kidney cancer in adults, and one of the most deadly.

04/15/2010

Oncology Investigators Leading Promising Research to be Awarded More Than $7.1 Million at the 2010 ASCO Annual Meeting

Tue, 13 Apr 2010 13:10:00 GMT

Each of this years 46 awardees will receive a 1-year grant of $50,000 to fund his or her investigative studies as they begin their careers in clinical oncology research. The Kidney Cancer Association is pleased to be a collaborator in funding these important grants.

04/14/2010

RCC treatment-related hypertension may be marker for efficacy

Tue, 13 Apr 2010 18:10:25 GMT

A retrospective, exploratory analysis of prospective clinical trials showed treatment-related hypertension was associated with significantly greater progression-free survival and overall survival in patients with metastatic renal cell carcinoma . . .

04/14/2010

AVEO Pharmaceuticals' Translational Research Platform and Novel Antibody Pipeline

Wed, 14 Apr 2010 13:56:22 GMT

Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types.

04/14/2010

Researchers find proteins to detect kidney cancer

Wed, 14 Apr 2010 13:59:05 GMT

The researchers identified a pair of proteins -- aquaporin-1, or AQP1, and adipophilin, or ADFP, -- that are excreted in the urine that could lead to earlier and more accurate diagnosis of the disease. The proteins were not elevated in people without cancer.

04/14/2010

AACR and Landon Foundation Support the Next Generation of Researchers with the INNOVATOR Awards

Wed, 14 Apr 2010 14:00:55 GMT

W. Kimryn Rathmell, M.D., Ph.D.'s project, Advancing Prognostic Algorithms for Renal Cell Carcinoma, focuses on renal cell carcinoma, a type of kidney cancer.

04/14/2010

Prognostic stratification of patients with advanced renal cell carcinoma

Wed, 14 Apr 2010 14:03:21 GMT

The treatment paradigm in advanced renal cell carcinoma (RCC) has changed in the recent years. Sunitinib has been established as a new standard for first-line therapy. We studied the prognostic significance of baseline characteristics and we compared the risk stratification with the established Memorial Sloan Kettering Cancer Center (MSKCC) model.

04/14/2010

Early 21st Century renal cell carcinoma

Wed, 14 Apr 2010 14:08:37 GMT

Individuals involved in the management of patients with small renal masses should acknowledge the role and the importance of active surveillance in older populations (aged >75 years) and minimally invasive ablative therapies. These new therapeutic strategies should be inculcated during medical training and practice so that they may become just as embedded as the emphasis on the oncologic outcome of standard treatment.

04/14/2010

Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma

Wed, 14 Apr 2010 14:09:52 GMT

Karyotypic analysis and genomic copy number analysis with single nucleotide polymorphism (SNP)-based microarrays were compared with regard to the detection of recurrent genomic imbalances in 20 clear cell renal cell carcinomas (ccRCCs).

04/14/2010

WSJ: The Separation of Health and State

Tue, 13 Apr 2010 18:08:58 GMT

What happens when all medical decisions are political.

04/13/2010

VIDEO: Association Board Chair Sarah Wise Miller

Tue, 13 Apr 2010 18:09:18 GMT

A few years ago, patients diagnosed with advanced kidney cancer had limited treatment options. However, in recent years, innovative targeted therapies have been developed that have helped countless patients delay the progression of the disease.

04/13/2010

VIDEO: Living With Kidney Cancer

Sun, 11 Apr 2010 22:08:24 GMT

Join Kidney Cancer Association Board Chair and kidney cancer survivor, Sarah Wise Miller, at either of these two great meetings for survivors and family members. Learn about living with kidney cancer from some of the world's leading experts. Register online by clicking "Calendar of Events" on the home page at KidneyCancer.org.

04/13/2010

Hallucinogens Have Doctors Tuning In Again

Mon, 12 Apr 2010 14:13:10 GMT

As a retired clinical psychologist, Clark Martin was well acquainted with traditional treatments for depression, but his own case seemed untreatable as he struggled through chemotherapy and other grueling regimens for kidney cancer. Counseling seemed futile to him. So did the antidepressant pills he tried.

04/13/2010

Keryx Biopharmaceuticals, Inc.

Tue, 13 Apr 2010 12:44:33 GMT

Keryx declared the results of the clinical activity of KRX-0401 (perifosine), the company´s Akt-inhibitor for cancer, to be used as a treatment for advanced renal cell carcnoma.

04/13/2010

EAU Congress in Barcelona tops attendance registrations

Tue, 13 Apr 2010 12:46:35 GMT

The congress will also tackle some of the most controversial issues in urology and the EAU's Scientific Committee has prepared a programme that covers a long list of urological topics ranging from paediatrics, bladder cancer, female urology, renal cell carcinoma, reconstruction and functional urology, benign prostatic obstruction, stones and minimal invasive therapy, to name a few. The Kidney Cancer Association is represented at this meeting through the participation of its board member and past chairman, Paula E. Bowen.

04/13/2010

The genetic link

Tue, 13 Apr 2010 12:49:09 GMT

HNPCC also raises the risk of other cancers, including ovarian, stomach, pancreatic and kidney cancer.

04/13/2010

An Evening of Reflection with Our Lady, Queen of Peace, and Visionary Ivan Dragicevic of Medjugorje

Tue, 13 Apr 2010 13:16:19 GMT

Boyle was diagnosed with renal cell carcinoma-a large tumor on his kidney . . . He was healed.

04/13/2010

The Massachusetts Insurance Blackout

Fri, 09 Apr 2010 13:25:01 GMT

This week it became impossible in Massachusetts for small businesses and individuals to buy health-care coverage after Governor Deval Patrick imposed price controls on premiums. Read on, because under ObamaCare this kind of political showdown will soon be coming to an insurance market near you.

04/12/2010

Wall Street Journal: Medical Privacy and ObamaCare

Fri, 09 Apr 2010 13:29:11 GMT

The Obama health law requires that nearly everyone enroll in a "qualified" plan, then says plans can pay only doctors who implement whatever regulations the Secretary of Health and Human Services imposes to improve health-care "quality" (Section 1311). That covers everything in medicine. Never has the federal government dictated how doctors treat privately insured patients . . .

04/12/2010

Clear Cell Histology Predicts Worse Prognosis With Kidney Cancer

Sat, 10 Apr 2010 14:11:35 GMT

The histological subtype of renal cell carcinoma predicts outcome, Mayo Clinic researchers say - but rather than settling the controversy over this issue, their assertion just adds to it.

04/12/2010

Primary malignant non-Wilms' renal tumours in children

Sat, 10 Apr 2010 14:13:07 GMT

Non-Wilms' tumours form a small heterogeneous group of clinically significant renal malignancies in children, including renal-cell carcinoma, clear-cell sarcoma, (congenital) mesoblastic nephroma, rhabdoid tumour, and renal medullary carcinoma.

04/12/2010

Final Analysis of Overall Survival (AVOREN)

Sat, 10 Apr 2010 14:15:32 GMT

A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC). Here, we report overall survival (OS) data.

04/12/2010

Cancer vaccines therapy

Sat, 10 Apr 2010 14:18:02 GMT

A new study, 'Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma,' is now available.

04/12/2010

St. Josephs Healthcare Hamilton launches kidney website

Sat, 10 Apr 2010 14:23:08 GMT

The website is a resource for those who are experiencing kidney ailments and to help individuals easily navigate on a user-friendly website that offers an abundance of helpful information, including Your Kidney which anatomically displays and details the kidney.

04/12/2010

Mother condemns NHS over cancer drug refusal

Sat, 10 Apr 2010 14:25:18 GMT

A mother from Kent dying of a rare form of cancer has hit out at the NHS after she was refused the only drug that could help prolong her life.

04/12/2010

Health insurance would cover drug trials under bill

Sun, 11 Apr 2010 16:55:23 GMT

The trial that Cutright enrolled in through the institute - part of Southern Illinois University School of Medicine - pays for the medicine Cutright hopes will halt or slow the progression of her adrenal cancer, which has spread to both lungs.

04/12/2010

Early Detection and Diagnosis

Wed, 07 Apr 2010 12:22:13 GMT

Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma.

04/11/2010

Hepatitis C Infection Doubles Risk for Kidney Cancer

Wed, 07 Apr 2010 12:25:26 GMT

Physicians at Henry Ford Hospital have found that infection with the hepatitis C virus increases the risk for developing kidney cancer.

04/11/2010

Cipla to launch kidney cancer drug at 1/10th of its price

Fri, 09 Apr 2010 12:52:07 GMT

"Cipla will launch ''sorafenib tosylate'' under the brand Soranib, the generic version of Nexavar at less than 1/10th of Bayer''s price of Rs 2.8 lakh for a month''s treatment," Cipla Joint Managing Director Amar Lulla told PTI over telephone.

04/11/2010

Mother forced to sell her home to buy cancer drugs

Fri, 09 Apr 2010 12:54:50 GMT

The rationing body NICE has since refused to approve ten such drugs. Experts say the rulings cut short up to 20,000 lives.

04/11/2010

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival

Fri, 09 Apr 2010 13:09:47 GMT

A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC).

04/11/2010

Survivors of Childhood Cancer Face Shortened Life Expectancy in Adulthood

Tue, 06 Apr 2010 12:24:15 GMT

The researchers found that survivors of childhood cancers face health risks that shorten their life span by about 10 years on average. The loss in life expectancy varied for different types of cancer. Survivors of kidney cancer died about 4 years earlier . . .

04/10/2010

Life-saving cancer drugs still not available on NHS

Tue, 06 Apr 2010 12:28:02 GMT

Life-saving cancer drugs are still not available on the NHS nearly 18 months after the Government promised to improve access to vital medicines, the Conservatives claim.

04/10/2010

What is TIVOZANIB?

Mon, 05 Apr 2010 15:25:34 GMT

In addition to our ongoing Phase 3 clinical trial of once-daily, oral tivozanib in patients with advanced RCC, we are currently conducting multiple clinical trials of tivozanib . . .

04/09/2010

The Onconeural Antigen cdr2 Is a Novel APC/C Target that Acts in Mitosis to Regulate C-Myc Target Genes in Mammalian Tumor Cells

Fri, 09 Apr 2010 13:03:53 GMT

Cdr2 is a tumor antigen expressed in a high percentage of breast and ovarian tumors and is the target of a naturally occurring tumor immune response in patients with paraneoplastic cerebellar degeneration, but little is known of its regulation or function in cancer cells. Here we find that cdr2 is cell cycle regulated in tumor cells with protein levels peaking in mitosis.

04/09/2010

Urine test for kidney cancer a step closer to development

Thu, 08 Apr 2010 01:34:37 GMT

Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.

04/08/2010

Kinase targets in renal-cell carcinomas

Thu, 08 Apr 2010 11:22:03 GMT

In this review, we discuss the use of molecularly-targeted kinase inhibitors in the treatment of renal-cell carcinoma and identify the next generation of kinase inhibitors that show promise for treatment.

04/08/2010

BNC105 US Renal Cancer Trial Initiated

Thu, 08 Apr 2010 11:27:39 GMT

The trial will determine whether BNC105 is effective in the treatment of progressive metastaticrenal cell carcinoma, either in combination with or following Afinitor (also known asEverolimus) treatment in patients who have disease progression following treatment withtyrosine kinase inhibitors such as Sutent or Nexavar.

04/08/2010

Has Cleveland State professor found a cure for cancer?

Sat, 03 Apr 2010 14:58:20 GMT

And it happened by accident. Right there inside chemistry labs in a science building along Euclid Avenue.

04/07/2010

The Do's & Don'ts of Managing Your Kidney Cancer Treatment

Sun, 04 Apr 2010 17:48:14 GMT

Ask Dr. DeSilva Internet radio program: Sarah Wise Miller, chairman of the Board of Directors of the Kidney Cancer Association and a ten-year survivor of Renal Cell Carcinoma joins the show to discuss the do's and dont's of managing your Kidney cancer treatment.

04/07/2010

New Topical Eye Drop for the Treatment of Macular Degeneration

Mon, 05 Apr 2010 13:29:01 GMT

According to Dr. Cohen, Pazopanib has been previously used in humans extensively as an oral agent for the treatment of renal cell carcinoma.

04/07/2010

Patients get life-saving drugs if Tories win

Mon, 05 Apr 2010 13:31:47 GMT

Mr. Cameron said: "Other European countries are giving people longer, happier lives with cancer than we are. Thousands whose doctors would like them to have a drug will get it."

04/07/2010

MP meets cancer patients in Witney

Wed, 07 Apr 2010 12:37:39 GMT

Witney MP and Conservative Party leader, David Cameron, met campaigners for kidney cancer drugs in Witney, where he outlined a plan for a cancer drugs fund.

04/07/2010

2nd Annual Michael J. Garner Renal Run 5k

Sun, 04 Apr 2010 16:15:02 GMT

This fun, family-friendly event, May 1, 2010, is held to honor Michael J. Garner, retired Tulsa Police Officer who lost his battle with kidney cancer in 2008.

04/06/2010

Santa Barbara: Annual All Sorority Volleyball Tournament

Sun, 04 Apr 2010 15:26:02 GMT

The Annual All Sorority Volleyball Tournament held at beautiful East Beach in downtown Santa Barbara, April 24, 2010. The entire UCSB and Santa Barbara community is invited, so come out and help us raise money for the Kidney Cancer Association, while enjoying a day at the beach with more than 30 sororities from all over California competing, food vendors, DJ's spinning all day, and a beer garden for those 21 and up.

04/05/2010

Seven things you can do if a loved one is diagnosed with cancer

Mon, 05 Apr 2010 15:56:44 GMT

Georgia Cancer Specialists nurse Kimberly Auriemma shares seven things you can do if one of your loved ones is diagnosed with cancer.

04/05/2010

Sorafenib and sunitinib increase risk of blood clots, research shows

Fri, 02 Apr 2010 14:46:30 GMT

Two cancer drugs triple the risk of blood clots in the arteries, a meta-analysis published online in the Journal of Clinical Oncology (29 March 2010) has found.

04/04/2010

Cancer patients 'are denied drugs'

Sat, 03 Apr 2010 13:12:53 GMT

Cancer sufferers in the UK are still failing to get drugs widely available elsewhere in Europe despite government efforts to speed up approvals, the Tories have said.

04/04/2010

'We'll sell our house for this drug'

Sat, 03 Apr 2010 13:26:40 GMT

"It's devastating for us, because three months ago, before Sutent, he was a dying man. Now he is unrecognisable, almost back to normal - it's clearly working for him."

04/04/2010

UK: Too many new cancer drugs turned down

Sat, 03 Apr 2010 13:33:05 GMT

A drug for advanced kidney cancer, Sutent, was recommended as the first treatment for patients in March 2009 after a vigorous campaign by doctors and patients. But three other drugs for the same type of cancer have had their application to be used as a first line treatment turned down by NICE.

04/04/2010

Gene discovery could lead to new treatments for childhood cancer

Sat, 03 Apr 2010 13:34:57 GMT

Cancer Research UK-funded scientists have identified two genes linked to Wilms tumour a type of childhood kidney cancer - according to research published in Clinical Cancer Research.

04/04/2010

Researchers and Scientists Honored for Improving Treatment and Quality of Life

Fri, 02 Apr 2010 14:36:26 GMT

Dr. McCormick is a pioneering molecular biologist and cancer researcher, whose contributions include the development of sorafenib, a small-molecule tyrosine protein kinase inhibitor used for the treatment of kidney cancer and advanced liver cancer.

04/03/2010

NICE: Percutaneous radiofrequency ablation of renal cancer

Fri, 02 Apr 2010 14:33:49 GMT

The National Institute for Health and Clinical Excellence (NICE) is examining percutaneous radiofrequency ablation of renal cancer and will publish guidance on its safety and efficacy to the NHS in England, Wales, Scotland and Northern Ireland.

04/03/2010

Lpath rejects Merck's proposal to extend the opt-in deadline for anti-cancer drug Asonep

Fri, 02 Apr 2010 14:43:51 GMT

These compelling factors include strong efficacy signals from a wide spectrum of preclinical studies in animal models involving renal cell carcinoma, prostate cancer, neuroblastoma, ovarian cancer, and lung cancer, and now the successful completion of the phase 1 trial announced today that demonstrated an excellent safety profile and produced evidence of pharmacological activity in cancer patients.

04/03/2010

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice

Fri, 02 Apr 2010 14:45:21 GMT

Cancer gene/virus therapy will not achieve its potential until vectors can be delivered systemically to metastatic disease.

04/03/2010

Changes in Renal Cell Carcinoma Symptoms Identified

Fri, 02 Apr 2010 00:40:07 GMT

Researchers who studied renal cell carcinoma (RCC) cases diagnosed between 1964 and 1997 observed an increase in the proportion of cases diagnosed incidentally during that period as well as a decrease in hematuria and elevated erythrocyte sedimentation rate (ESR) as presenting symptoms.

04/02/2010

Higher vitamin K intake tied to lower cancer risks

Fri, 02 Apr 2010 00:43:44 GMT

People with higher intakes of vitamin K from food may be less likely to develop or die of cancer, particularly lung or prostate cancers, than those who eat relatively few vitamin-K- containing foods, a new study suggests.

04/02/2010

Sunitinib, sorafenib increased risk for arterial thrombosis threefold

Thu, 01 Apr 2010 16:13:54 GMT

The use of the oral vascular endothelial growth factor receptor tyrosine kinase inhibitors sunitinib and sorafenib resulted in a threefold increased relative risk for arterial thrombosis, according to the results of a meta-analysis.

04/02/2010

2010 ASCO Tumor Boards: Renal Cell Carcinoma

Thu, 01 Apr 2010 14:12:08 GMT

In this month's Tumor Board, Christopher Wood, MD, FACS, and David Nanus, MD, focus on a patient with advanced renal cell carcinoma (RCC).

04/02/2010

Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma

Thu, 01 Apr 2010 14:08:34 GMT

Bilateral spontaneous pneumothorax is a rare occurrence in patients with both primary and metastatic lung cancer. Pneumothorax occurring as a complication of vascular endothelial growth factor receptor (VEGFR) inhibitor therapy has not been previously described in the medical literature. Sunitinib malate is a VEGFR inhibitor approved for the treatment of advanced renal cell carcinoma. We present a patient with metastatic renal cell carcinoma manifested as bilateral pulmonary nodules who developed a bilateral spontaneous pneumothorax 3 weeks after initiation of sunitinib therapy.

04/01/2010

New diagnostic methods and therapeutics

Thu, 01 Apr 2010 13:55:00 GMT

We are studying serum and tissue markers that can be used in screening and diagnosis of kidney cancer.

04/01/2010

Pathways involved in Wilms tumor

Thu, 01 Apr 2010 13:52:37 GMT

Wilms tumor, the most common pediatric kidney cancer, is a pluripotent tumor that arises in kidney specific stem cells and histologically resembles the earliest stages of kidney development.

04/01/2010

CaringBridge: Warren Lewis

Fri, 02 Apr 2010 00:45:47 GMT

We have created this caringbridge site at the suggestion of family & friends to keep everyone updated on Warren. We are doing well and appreciate everyone's love, support & kindness.

04/01/2010

Kidney Cancer Education and Support Meetings

Wed, 31 Mar 2010 17:10:21 GMT

Nearly 30 meetings are scheduled through June, 2010, in both the USA and Europe, including large, day-long, meetings in Houston and London.

04/01/2010

Sunlight Exposure Reduces Kidney Cancer Risk in Men

Thu, 01 Apr 2010 03:14:39 GMT

Published early online in Cancer the study is the largest case-control study of kidney cancer to investigate the association with occupational sunlight exposure. American Cancer Society (2010, March 8). Occupational sunlight exposure reduces kidney cancer risk in men, study suggests.

04/01/2010

Is the Tanning Tax Half Baked?

Thu, 01 Apr 2010 03:16:39 GMT

The horse-trading that helped win doctors support for the health-care overhaul included replacing a proposed 5% tax on Botox treatments and elective cosmetic procedures with a 10% tax on indoor tanning services.

04/01/2010

Surveillance of renal cortical neoplasm an option in some elderly

Thu, 01 Apr 2010 14:13:20 GMT

Active surveillance for renal cortical neoplasm is a "reasonable treatment option" in older patients with comorbid illness, according to a single-center report from Columbia University in New York.

04/01/2010

Larry R. Mummey

Thu, 01 Apr 2010 14:14:33 GMT

Larry R. Mummey, 66, a master chief in the Navy, died March 18, 2010, from complications due to kidney cancer.

04/01/2010

Current Oncology: Sunitinib Causes Macrocytosis

Thu, 01 Apr 2010 15:04:59 GMT

Sunitinib Causes Macrocytosis in Patients with Advance Renal Cell Carcinoma (RCC)

04/01/2010

Renal Cell Carcinoma Type Linked to Time on Dialysis

Wed, 31 Mar 2010 12:48:50 GMT

The histologic type of renal cell carcinoma (RCC) arising in patients with end-stage renal disease (ESRD) may be related to the time on dialysis, according to a study.

03/31/2010

Overwhelming Public Anger Over US Government Policies

Wed, 31 Mar 2010 12:37:16 GMT

03/31/2010

Risk factors and clinical management of haemorrhage after open nephron-sparing surgery

Wed, 31 Mar 2010 12:44:36 GMT

We evaluated bleeding complications after open NSS in 196 consecutive cases (193 patients) at our institution.

03/31/2010

Kingdom records 200 kidney cancer cases per annum

Wed, 31 Mar 2010 12:45:59 GMT

Speaking on the sidelines of the recent Saudi Conference on Urological Tumors in Sharm Al-Sheikh in Egypt, Abu Samra said that studies showed a growth in kidney cancer worldwide, but particularly in the Arab World.

03/31/2010

Possible Link Between Opioids and Cancer Progression

Tue, 30 Mar 2010 15:53:35 GMT

Two recent studies conducted by researchers at the University of Chicago add to a growing literature that suggest that opioid-based pain therapies may trigger the growth and migration of cancer cells.

03/31/2010

Kidney Cancer Films: Jane's Journey

Fri, 02 Apr 2010 00:49:03 GMT

The film 'Kidney Cancer: Jane's Journey' was commissioned by the James Whale Fund for Kidney Cancer (http://www.jameswhalefund.org /) and Kidney Cancer UK (http://www.kcuk.org/) in co-sponsorship with Novartis Oncology, Red Health and Day for Night Films, to raise awareness of this cruel disease.

03/31/2010

What Does Health Care Reform Mean for Patients?

Tue, 30 Mar 2010 15:14:10 GMT

Now that it has passed, lets take a look at how the bill will affect the average patient.

03/31/2010

US judge strikes down patent on cancer genes

Tue, 30 Mar 2010 14:19:42 GMT

The decision by U.S. District Judge Robert Sweet challenging whether anyone can hold patents on human genes was expected to have broad implications for the biotechnology industry and genetics-based medical research.

03/30/2010

Surgery gives kidney cancer patient 2nd chance

Tue, 30 Mar 2010 14:54:41 GMT

A kidney cancer patient who underwent surgery at the Mayo Clinic shared her story in this week's Medical Edge.

03/30/2010

Metronomic chemotherapy for renal cancer

Tue, 30 Mar 2010 14:58:16 GMT

The paper by Bellmunt and colleagues, 1 published in this issue of The Lancet Oncology , could be regarded as a challenge to the conventional approach...

03/30/2010

Epithelial to Mesenchymal Transition in Human Skin Wound Healing

Tue, 30 Mar 2010 15:02:11 GMT

Epithelial-mesenchymal transition (EMT), characterized by loss of epithelial adhesion and gain of mesenchymal features, is an important mechanism to empower epithelial cells into the motility that occurs during embryonic development and recurs in cancer and fibrosis . . .

03/30/2010

Pathological prognostic indicators in renal cell carcinoma

Tue, 30 Mar 2010 15:04:01 GMT

To analyze histological factors not routinely assessed as potential prognostic factors in renal cell carcinoma, such as tumor necrosis, microscopic vascular invasion, and sinus fat invasion.

03/30/2010

Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib

Tue, 30 Mar 2010 15:19:34 GMT

Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) used in a vast range of cancers. Arterial thromboembolic events (ATE) have been described with these agents, although the overall risk remains unclear.

03/30/2010

Unclassified Renal Cell Carcinoma

Tue, 30 Mar 2010 15:21:47 GMT

Although URCC is more likely to present with advanced clinicopathologic features compared with ccRCC . . .

03/30/2010

Treatments for Advanced Renal Cancer

Mon, 29 Mar 2010 13:21:11 GMT

This video features a kidney cancer survivor, along with members of the Kidney Cancer Association's governing and medical boards, who have conducted ground-breaking research in the treatment of kidney cancer.

03/29/2010

ObamaCare and Immigration Reform

Mon, 29 Mar 2010 13:46:28 GMT

...a larger welfare state is not conducive to comprehensive immigration reform. If foreigners start coming for handouts instead of economic opportunity, tighter restrictions will be justified.

03/29/2010

Total Fluid And Specific Beverage Intake And Risk Of Renal Cell Carcinoma In Canada

Mon, 29 Mar 2010 13:51:52 GMT

This is a large, nationwide, population-based investigation based on a widely used and validated food frequency questionnaire (FFQ). Nevertheless, possible limitations should be mentioned, in particular, the validity of information on intake of beverages 2 years before the study.

03/29/2010

Kidney Cancer Risk Groups

Mon, 29 Mar 2010 13:54:10 GMT

This video features members of our Kidney Cancer Association Professional Group, along with kidney cancer survivors.

03/29/2010

"We Have Kidney Cancer" Facebook Fan Page

Mon, 29 Mar 2010 14:55:07 GMT

We Have Kidney Cancer

Promote Your Page Too

03/29/2010

ASCO Statement on the Passage of the Patient Protection and Affordable Health Care Act

Tue, 30 Mar 2010 04:07:30 GMT

While ASCO recognizes that there are strong feelings on both sides of this issue, we are very pleased that the newly passed Patient Protection and Affordable Care Act signed into law this week includes a number of things that will benefit cancer patients in the short term...

03/29/2010

The Kidney Cancer Association challenge focuses on Facebook Fans

Sun, 28 Mar 2010 15:28:01 GMT

"Today, social networks, like Facebook, play an important role in the lives of families that are dealing with a loved one's experience with cancer," Bro said. "Families are using social media more than ever before to engage friends and share information. There's great economy in this, because it saves the time that would have been spent updating distant family members, colleagues, and friends in individual telephone calls. Some of these precious lost minutes could be better spent helping the patient to become a survivor. [Ed.] Since the original publication of this article, the Facebook challenge has been modified. If the KCA's Facebook Fan Page accrues 5,000 fans by the end of March, the charity is eligible to receive gifts totaling $2,000.00--100% more than the original challenge grant.]

03/28/2010

Renal cancer and chronic kidney disease

Sat, 27 Mar 2010 17:59:18 GMT

Does CKD or ESRD lead to kidney cancer?

03/28/2010

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma

Sun, 28 Mar 2010 15:18:38 GMT

Historically, there have been few treatment options for patients with advanced renal cell carcinoma (RCC) besides immunotherapy with interleukin-2 and interferon (IFN)-{alpha}. Targeted therapies have improved clinical outcomes over the past several years. These include the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors sunitinib and sorafenib, which inhibit angiogenic signaling in endothelial cells and vascular pericytes predominantly through VEGFR and platelet-derived growth factor receptor β.

03/28/2010

Reports on renal cell carcinoma immunotherapy findings from Royal Marsden Hospital provide new insights

Sun, 28 Mar 2010 15:20:35 GMT

Researchers detail in 'Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial,' new data in renal cell carcinoma.

03/28/2010

Kidney Cancer Treatments

Mon, 29 Mar 2010 13:17:00 GMT

According to the American Cancer Society, about 32,000 new cases of Kidney cancer are diagnosed and about 12,000 people die from the disease annually.

03/27/2010

The Do's & Don'ts of Managing Your Kidney Cancer Treatment

Sat, 27 Mar 2010 14:37:06 GMT

Health Radio: Sarah Wise Miller, chairman of the Board of Directors of the Kidney Cancer Association and a ten-year survivor of Renal Cell Carcinoma joins host Dr. Derrick DeSilva to discuss the do's and dont's of managing your Kidney cancer treatment.

03/27/2010

Impact of body mass index on perioperative outcomes of laparoscopic radical nephrectomy

Sat, 27 Mar 2010 16:06:26 GMT

The aim of this study was to review the association between body mass index (BMI) and perioperative outcomes of laparoscopic radical nephrectomy (LRN) in Japanese patients with renal cell carcinoma (RCC).

03/27/2010

Saskatchewan now covering cost of kidney cancer drug Torisel

Thu, 25 Mar 2010 14:11:40 GMT

Saskatchewan has joined two other Canadian provinces that cover the cost of Torisel , a drug used in the treatment of advanced kidney cancer. In clinical studies, compared to Interferon-alpha, recognized as the standard of care, Torisel significantly increased survival from diagnosis to death by 49 per cent.

Bill Bro, CEO of the Kidney Cancer Association (KCA), a global patient advocacy organization, said, "It's comforting to know that many Canadians now have the same therapeutic options for treatment of renal cancer that patients here in the United States have had for quite some time. The limited access to these novel therapies in countries where sociailized medicine prevails continues to be of great concern to our charity. We'll continue fighting for these patients living where their medical system kicks them to the curb, because this cancer is an expensive one to treat. Novel therapies continue to signfificantly improve the quality of life for these desperately ill people."

The KCA reaches 50,000 people in more than 100 countries, from its offices in suburban Chicago. It is the largest organization of its kind, serving the needs of patients and medical practicioners. The KCA was founded by Eugene P. Schonfeld, Ph.D., and a small group of patients, in 1990.

03/26/2010

THE MEDIAN ISN'T THE MESSAGE

Fri, 26 Mar 2010 00:19:44 GMT

"This is a personal story of statistics..."

03/26/2010

Rexahn Pharma sets up advisory board

Thu, 25 Mar 2010 13:49:47 GMT

All three drugs are potentially best-in-class pharmaceuticals.

03/25/2010

How Not to Miss or Mischaracterize a Renal Cell Carcinoma: Protocols, Pearls, and Pitfalls

Thu, 25 Mar 2010 13:51:49 GMT

Proper data acquisition and utilization of postprocessing tools are essential to avoid missed diagnoses or misinterpretation when imaging renal cell carcinoma.

03/25/2010

Wilex Enters 20M Standby Equity Deal with Yorkville

Thu, 25 Mar 2010 13:54:53 GMT

The upcoming quarter is crucial for Wilex, as it is due to report data from two key clinical trials during the period. It will report final data from a Phase III trial of Redectane (girentuximab), a radiolabeled antibody in development for presurgical detection of clear cell renal cell carcinoma, the most common form of kidney cancer. A regulatory filing could follow in the fourth quarter.

03/25/2010

Congressional Kidney Caucus Praises KCA

Mon, 22 Mar 2010 13:52:48 GMT

03/24/2010

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells

Tue, 23 Mar 2010 20:23:32 GMT

Transplanted donor lymphocytes infused during hematopoietic stem cell transplantation (HSCT) have been shown to cure patients with hematological malignancies.

03/23/2010

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

Tue, 23 Mar 2010 20:24:49 GMT

Cancer immunotherapy involving natural killer (NK) cell infusions and administration of therapeutic agents modulating the susceptibility of tumors to NK-cell lysis has been proposed recently.

03/23/2010

Benzene has been connected to a rare form of kidney cancer

Tue, 23 Mar 2010 19:47:12 GMT

The US Department of Health and Human Services (DHHS) classifies benzene as a human carcinogen.

03/23/2010

Update on Washington Secretary of State Reed's cancer

Tue, 23 Mar 2010 19:49:06 GMT

Reed's office announced last week that he had been diagnosed with kidney cancer.

03/23/2010

Virtual colonoscopy allows detection of unsuspected cancers beyond colon

Tue, 23 Mar 2010 19:51:25 GMT

Extracolonic malignancies, which outnumbered cases of invasive colorectal cancer, included renal cell carcinoma, lung cancer and non-Hodgkin lymphoma, among others.

03/23/2010

KCA Recognized by ASCO Cancer Foundation®

Mon, 22 Mar 2010 13:55:10 GMT

List of Foundations and Non-Profit Organizations

03/22/2010

XM Radio: Dr. Samir Taneja

Mon, 22 Mar 2010 14:06:12 GMT

"Doctor Radio" host specializes in kidney cancer surgery.

03/22/2010

Ambitious climb honors dad who suffered from kidney cancer

Sun, 21 Mar 2010 14:46:29 GMT

"It's called Kidney Klimb. We hope to raise $10,000 for kidney cancer awareness and for families in the area who are dealing with this. The bulk of our money will go to families, but we will give some to the Kidney Cancer Association..."

03/22/2010

Former PR exec for Disney and Irvine Co. dies

Mon, 22 Mar 2010 14:08:39 GMT

C. Thomas Wilck, 75, died July 24 from kidney cancer.

03/22/2010

Laparoscopic Radical Nephrectomy For Renal Cell Carcinoma

Fri, 19 Mar 2010 15:13:14 GMT

In 73 patients with kidney cancer undergoing laparoscopic radical nephrectomy and followed for mean 11.2 years, cancer-specific and overall survival were 78% and 35%, respectively. Cancer recurred in 11% of patients; in 7%, the recurrence occurred late at 8-10 years after surgery.

03/21/2010

Loss of expression of TIMP3 in clear cell renal cell carcinoma

Fri, 19 Mar 2010 15:17:41 GMT

In clear cell renal cell carcinoma (CCRCC), vascular endothelial growth factor (VEGF) represents the central positive mediator of tumour angiogenesis while VEGF receptor (VEGFR) is the primary target of anti-angiogenic therapies. TIMP3 is a physiological VEGFR-2 antagonist and thus could be considered as an anti-angiogenic factor. We therefore determined the status of this physiological inhibitor in CCRCC.

03/21/2010

UK cancer death risk is 70% higher in men

Fri, 19 Mar 2010 15:10:02 GMT

Unhealthy lifestyles and a 'stiff upper lip' make men up to 70 per cent more likely to die from cancer than women, doctors have warned.

03/20/2010

Roche Increased Avastin Sales Efforts; Doubles US Force

Fri, 19 Mar 2010 15:11:40 GMT

The moves come after Roche paid $46.8 billion to takeover Genentech Inc., which developed the drug. Avastin was Roche's biggest seller in 2009 with sales of about $5.9 billion, making up about 13% of its total, but it has faced multiple setbacks in its development since the deal closed about a year ago.

03/20/2010

Orangeburg man runs marathon to raise $50K for KCA

Mon, 15 Mar 2010 14:32:25 GMT

He plans to run in the New York City Half-Marathon on March 21. He hopes to raise $50,000 for the Kidney Cancer Association.

03/19/2010

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic

Tue, 16 Mar 2010 13:03:55 GMT

Proteomics and subsequent validation yielded two novel prognostic markers and survival models which improved prediction of OS in mRCC patients over commonly used risk models. Implementation of these models has the potential to improve current risk stratification, although prospective validation will still be necessary.

03/19/2010

Secretary of State Sam Reed has kidney cancer

Thu, 18 Mar 2010 14:01:08 GMT

Spokesman David Ammons said Wednesday that Reed was diagnosed last week. He has a malignant tumor on his left kidney, and surgeons will remove the entire kidney on Monday at Virginia Mason Medical Center in Seattle.

03/19/2010

NICE leaves many patients with rarer forms of cancer without drugs

Thu, 18 Mar 2010 14:04:12 GMT

The National Institute for Health and Clinical Excellence (NICE) is failing to follow its own guidance aimed at making live-extending treatments available on the NHS, leaving many patients with rarer forms of cancer without drugs that could prolong their lives, a campaign group has said.

03/19/2010

Senators question $1 million pay for charity's CEO

03/07/2010

Tue, 02 Mar 2010 14:19:24 GMT

With the advent of the new targeted therapies there has been a complete shift in paradigm. Treatment options for patients with advanced disease have improved dramatically; until recently there was limited choice and therapies were poorly tolerated, with relatively low response rates. Patients now face multiple options with improved safety and efficacy, and there are plenty of further therapies in the pipeline. The overall prognosis has changed for these patients and survival is now much longer.

03/02/2010

FactCheck.org: Republican & Democrat Health Reform Plans

Tue, 02 Mar 2010 14:57:01 GMT

Contrary to claims made by some Democratic detractors, detailed GOP proposals, and a bipartisan bill with several GOP cosponsors, do exist.

03/02/2010

Sun, 28 Feb 2010 22:23:29 GMT

In this email to our CEO, Bill Bro, Shannon Bell, Director, Office of Advocacy Relations, at the National Cancer Institute, describes new initiatives in kidney cancer research. Mr. Bro will attend the National Cancer Advisory Board meetings, in Bethesda, in his capacity as a liaison representing cancer survivors.

Dear Bill:

I would like to take this opportunity to call your attention to several of NCI’s exciting initiatives funded through the American Recovery and Reinvestment Act of 2009 (ARRA) in both cancer research generally and in kidney cancer specifically. I am pleased to report that the National Cancer Institute (NCI) has made significant strides in distributing the $1.26 billion it received under ARRA. As of mid-November 2009, the NCI has awarded $847 million in ARRA funds. These awards have enabled us to significantly expand our support of cancer research by increasing the percentage of grants funded, launching new interdisciplinary and collaborative programs, and accelerating clinical trials to get treatments to cancer patients more rapidly. These NCI ARRA investments are not only stimulating the economy through the support of biomedical and behavioral research, they are enabling opportunities for important scientific advances in cancer research. More detail about NCI’s use of ARRA funds can be found at: http://www.cancer.gov/recovery.

To advance our efforts in the area of kidney cancer, the NCI has used ARRA funds to award 46 grants totaling $3,162,070. These awards, uniquely identified by project numbers, complement our existing portfolio and stimulate the economy by supporting research at 38 institutions in 22 states across the country. Individual investigators conducting hypothesis-driven science remain the backbone of NCI’s research portfolio, and for that reason, the support of investigators—established or new to the field—was the institute’s first priority. Thus, 4 of the awards are funding investigator-initiated research, using the R01 funding mechanism.

For example, one R01 grant recipient (Project # 3R01CA104505-05S1) aims to understand the molecular pathways that underlie renal cell carcinoma, which could support the development of effective therapy for this disease. Another grantee (Project # 3R01CA054498-18S1) will study the long term health of patients treated for Wilms tumor (WT) during their childhood and will monitor the patients’ offspring for cancer and birth defects. By elucidating the late complications of WT and its treatment, and by identifying susceptible subgroups, this study will enable future generations of childhood cancer patients and their physicians to select optimum treatments based on knowledge of long term risks as well as short term benefits.

ARRA funds are also being used to increase the number of studies under TARGET (Therapeutically Applicable Research to Generate Effective Treatments), an initiative which will expand research on the molecular basis of childhood cancers http://target.cancer.gov/. The $25 million award to the TARGET initiative will allow NCI to further support two current TARGET projects and expand to include molecular characterization of three additional childhood tumors including Wilms tumor.

Remaining ARRA funds may be used to support additional kidney cancer research. To view research projects funded since November 2009, please visit the NIH Research Portfolio Online Reporting Tool (RePORT) at http://projectreporter.nih.gov/reporter.cfm. To research NCI ARRA funded kidney cancer projects: 1) be sure to mark the box “Show only projects supported by NIH Recovery Act funds”, 2) include ‘kidney cancer’ as a search term, and 3) check the NCI as the Agency/Institute/Center you wish to search. To view the Institute’s funded research grants, contract awards, and intramural research projects prior to FY 2009, please visit the NCI Funded Research Portfolio at: http://fundedresearch.cancer.gov/.

Thank you for your support of cancer research and the NCI. Please do not hesitate to contact me or members of my staff should you have further questions or require additional information.

Best regards,

Shannon K. Bell, MSW

Director, Office of Advocacy Relations

National Cancer Institute, NIH

Bethesda, MD 20892-2580

02/27/2010

News from Kidney Cancer Association

Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

Is it possible to detect early symptoms of Wilms' tumor?

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

Promise Of Tumor Ablation

Sequential use of targeted agents in the treatment of renal cell carcinoma

Nanoknife® Cancer Killer

Xp11 Translocation Renal Cell Carcinoma

Kidney Cancer 101: Learn Here

Join the International Kidney Cancer Alliance

Solid Variant of Papillary Renal Cell Carcinoma With Spindle Cell and Tubular Components

Differentiation of oncocytoma and renal cell carcinoma in small renal masses

Virtual colonoscopy catches more, study finds

Kidney patient gets transplanted to television

Lack of KISS1R expression is associated with rapid progression of conventional renal cell carcinomas

Is advanced renal cell carcinoma becoming a chronic disease?

Top Abstracts in Renal Cancer

Vanishing Cancers: Sometimes the disease simply disappears

Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma

Billionaire Giving Pledge Is A Bad Idea

GenSpera Receives Additional Patent

Latest Increase in U.S. Obesity Rate Will Mean More Cancers

Surviving Kidney Cancer

Virginia and Missouri fire shots over Obamacare's bow

Doctors say treatments using adult stem cells show promise

Molecular Diagnostics Conference In Denver To Be Hosted By American Association For Cancer Research

Lpath, the Category Leader of Lipidomics-Based Therapeutics, Provides Status Update

Advances in Renal Cancer Journalists Award 2011 announced

Biomarkers Predicting Outcome in Patients With Advanced Renal Cell Carcinoma

Wife vows to starve herself if NHS won't help her husband

Kidney Cancer Blog Has Info That Could Save Your Life

Cedar Hill woman turns her misery into ministry

"Advances in Renal Cancer" Journalists' Award 2011 announced Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer

Penn State Lift For Life Raises More Than $98,000.00

When Kidney Cancer Hits the Vena Cava

Kidney Removal Suggested Not To Prolong Life of Elderly

Lift for Life Raises New Record Total

Nationally-Recognized Oncologist Joins Cedars-Sinais Samuel Oschin Comprehensive Cancer Institute

Penn State football players raise $98,461.35 for kidney cancer research

Nanoparticles Shrink Tumors in Mice

First Patient Treated in Galil Medical's TRACE Renal Registry

PHOTO GALLERY: 2010 Penn State Lift for Life

Facebook Ad Campaign Raises Awareness

Survivor Gets Back on Course

Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus

New findings from University Hospital, Department of Urology in the area of renal cell carcinoma described

Didcot cancer patient's death linked to drug trial

Renal Cancer Associated With Recurrent Spontaneous Pneumothorax In Birt-Hogg-Dube Syndrome

Abscess Formation Mimicking Disease Progression

Exceeding Contrast Dose Threshold Increases Risk of Acute Kidney Injury

Cancer Treatment Based on Patient's Own Cells

Ill ex-prison employees blame work program

Rosetta Genomics and Collaborators Demonstrate MicroRNAs Accurately Sub-Classify Renal Tumors

Epithelioid angiomyolipoma of kidney with atypical nuclear features and intranuclear inclusions on cytology

Macrophages and Immunologic Inflammation of the Kidney

Pazopanib given conditional UK licence for advanced renal cell carcinoma

New Tool for Presurgical Detection of Kidney Cancers Helps to Avoid Unnecessary Surgeries

Concomitant Tumor and Autoantigen Vaccination Supports Renal Cell Carcinoma Rejection

Use of gene expression profiling to predict survival in cancer

RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma

Charity Navigator: Kidney Cancer Association

Concurrent Multilocular Cystic Renal Cell Carcinoma and Leiomyoma in the Same Kidney

Bone metastases from renal cell carcinoma: patient survival after surgical treatment

Total Pancreatectomy for Metastatic Renal Cell Carcinoma with Marked Extension into the Main Pancreatic Duct

Metastatic Tumor in the Colon from Renal Cell Carcinoma

Pure Sarcomatous Recurrence of Clear Cell Renal Carcinoma Following Radical Nephrectomy and Dendritic Cell Vaccination

TLN-4601

Kidney cancer patients denied drug that can extend their lives

Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma

1H NMR Metabonomic Analysis in Renal Cell Carcinoma: a Possible Diagnostic Tool

Treatment of Transitional Cell Cancer of the Renal Pelvis and Ureter in India at an Incredible Success Rate

Report on Clinical Integration of New Cancer Developments

Gene Mutation Linked to Kidney Cancer

Preclinical Data for MGCD265

Avastin May Cause Kidney Damage

Longtime football coach Ken Hovet dies of cancer

AVEO Pharmaceuticals Human Response Platform and Proprietary Mouse Models Featured in Nature Reviews Cancer

Laparo-endoscopic single-site (LESS) radical nephrectomy with renal vein thrombectomy: initial report

MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens

Advances in Renal Cancer Journalists Award 2011 announced

Lift for Life Raises New Record Total

Nationally-Recognized Oncologist Joins Cedars-Sinais Samuel Oschin Comprehensive Cancer Institute

AVEO Pharmaceuticals Human Response Platform and Proprietary Mouse Models Featured in Nature Reviews Cancer

Phase I Study of Single-Agent AntiProgrammed Death-1 (MDX-1106) in Refractory Solid Tumors

Distant Metastasis of Renal Cell Carcinoma With a Diameter of 3 cm or LessWhich is Aggressive Cancer